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The genus Streptococcus of the family Streptococcaceae consists of over 20 
identified species, only some of them being pathogenic for humans [1]. In relation to 
childbirth, group В streptococcus (Streptococcus agalactiae, GBS) and group A 
streptococcus (Streptococcus pyogenes) are important pathogens. Some important clinical 
differences as well as parallels between these two species have been established during the 
past two centuries. Knowledge regarding these points is relevant in view of the 
implications for prevention of infectious diseases due to these organisms. 
Historical perspective 
Historically, GBS was considered as a cause of bovine mastitis (Nocard and 
Mollereau, 1887) and was named accordingly [2]. The species name passed through many 
changes during the first half century after its discovery: S. nocardi, S. mastitis 
contagiosae, S. mastitis sporadicae, S. agalactiae contagiosae, S. agalactiae, S. mastitidis 
and a few others. The contemporary, officially valid name of the species, S. agalactiae, 
was proposed by Brown at the Fourth International Congress of Microbiology in 1947 
[3]. Although known in veterinary medicine, GBS was virtually ignored as human 
pathogen until the late 1930s. In 1935 Lancefield and Hare identified GBS in vaginal 
cultures from asymptomatic postpartum women [4]. Fry described three cases of fatal 
puerperal sepsis and was the first to report on GBS as human pathogen [5]. Neonatal 
meningitis due to GBS was reported first in 1958 by Nyhan and Fousek [6]. In the 1960s 
Hood et al., Eickhoff et al. and Butter and de Moor noted the role of GBS in perinatal 
infections [7-9]. Subsequently, an increasing number of studies in the obstetric and 
pediatric literature documented a growing concern with neonatal sepsis and/or meningitis 
due to GBS. By the early 1970s, the importance of GBS as a human pathogen could no 
longer be overlooked. Gradually, GBS replaced Escherichia coli as the most frequent 
microorganism associated with bacteremia or meningitis among infants during the first 
months of life [10]. Moreover, GBS has been identified as an important pathogen in 
obstetrical patients as well [11]. Manifestations include chorioamnionitis, postpartum 
endometritis (particularly after caesarean section) and urinary tract infections. 
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In the perinatal field, another species of the genus Streptococcus represents a well-
known pathogen: the group A streptococcus {Streptococcus pyogenes). This ubiquitous 
species can be an important pathogen of humans. It has the propensity to initiate two 
nonsuppurative sequelae: acute rheumatic fever and poststreptococcal acute 
glomerulonephritis. Puerperal sepsis follows abortion or delivery when group A 
streptococci invade the endometrium and surrounding structures, lymphatics and blood 
stream. The resulting endometritis and septicemia may be complicated by pelvic cellulitis, 
septic pelvic thrombophlebitis, peritonitis or pelvic abscess. Prior to the introduction of 
penicillin, this organism was the major cause of puerperal sepsis and was responsible for 
75 % of maternal mortality due to infection. 
The epidemic character and contagiousness of childbed fever was already noted in 
1773 by Charles White, a physician in Manchester, England, and in 1795 by his 
colleague Alexander Gordon in Aberdeen, Scotland [12]. In 1843, the United States 
physician Oliver Wendell Holmes (1809-1894) reported that puerperal fever was 
contagious, and was carried from bed to bed by the unwashed hands of physicians [13]. 
His contemporary European counterpart in the conquest of puerperal fever was Ignaz 
Philipp Semmelweis (1818-1865). In 1844 Semmelweis, a native of Hungary, was 
appointed assistant lecturer in the first obstetrical division of Vienna's Allgemeines 
Krankenhaus where medical students received their training. He was impressed by the 
high mortality rate of puerperal fever in this division: 16% between 1841 and 1843. He 
noted that the mortality rate due to puerperal fever was much lower, about 2%, in the 
hospital's second obstetrical division where all deliveries were performed by midwives. 
Semmelweis also observed the negligible mortality among the women who gave birth 
before reaching the hospital and hence without internal examinations during labor. 
Convinced that the true etiology was to be found in a factor that was endemic in the first 
obstetrical division, he studied and rejected many possible factors. It was the death of his 
friend and colleague Jakob Kolletschka resulting from an accidental cut during an autopsy 
that revealed him an identity with the fatal puerperal cases. He concluded that medical 
students transmitted infective material directly from the autopsy dissecting rooms to the 
delivery room. After reviewing maternal mortality data back to 1784, Semmelweis not 
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only noted the different rates in the two obstetrical divisions after their separation in 
1840, but also that puerperal fever rates in Vienna soared with the development of 
scientific medicine with its emphasis on the autopsy from the 1820s onwards. In 1847 he 
posted an order in his clinic, requiring the students to scrub their hands in a chlorinated 
lime solution before entering the maternity ward. Within a few months the mortality from 
puerperal fever fell dramatically (figure 1). He also concluded that examiners might 
transmit infection from live patients as well as from the dead and ordered his students to 
scrub with the chlorine solution before every physical examination [14]. 
Being unfamiliar with foreign languages. Semmelweis remained ignorant of the 
findings of Holmes. Like Holmes, whose teachings met with opposition in the United 
States, Semmelweis was attacked by European authorities. Four years before his death, in 
1861, his views were published under the title 'Die Aetiologie, der Begriff und die 
Prophylaxis des Kindbettfiebers' [15]. In the years after his death the doctrine of 
Semmelweis gradually achieved general acceptance in the medical community. 
Streptococci were demonstrated in cases of erysipelas and wound infections by 
Billroth in 1874 and in the blood of a patient with puerperal sepsis by Pasteur in 1879. 
Rosenbach applied the designation Streptococcus pyogenes to this organism in 1884 [1]. 
During an outbreak of puerperal fever in New York in 1927 the responsible bacteria was 
shown to be a group A ß-hemolytic streptococcus [16,17]. In the twentieth century the 
prevalence of serious streptococcal infections showed a further decline, probably due to 
improved socioeconomic conditions, greater attention to aseptic techniques and later on, 
the availability of antibiotics. A decreased prevalence of virulent streptococcal strains 
possibly also contributed to this decline that continued until the 1980s [18,19]. 
In the second half of the 1980s, reports both from the United States and Europe 
have suggested that there has been a resurgence of virulent group A streptococci, which 
cause sepsis, severe soft tissue invasion, symptoms associated with toxic shock syndrome 
and disseminated intravascular coagulation [20,21]. Life-threatening puerperal infections 
seem to have returned as well, raising new concerns about this age-old pathogen [22-25]. 
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Бя starben mithin von den innerhalb sieben Monaten ver­
pflegten 1841 Wöchnerinnen 56, 3.„. Im Jahre 1846, in 
welchem die Ghlorwaschungen noch nicht im Gebrauche wa-
ren, starben von 4010 an der enten Gebarklinik verpflegten 
Wöchnerinnen 459, d. i. 11.4 Percent An der zweiten Ab-
theilung starben im Jahre 1846 von 3754 Wöchnerinnen 105, 
d. i. 2.t Percent. Im Jahre 1847, wu gegen Mitte Mai die 
Chlonraeolrangen eingeführt warden, starben an der eraten 
Abtheilung von 3490 verpflegten Wöchnerinnen 176, d. i. 6.. 
Percent An der «weiten Abtheilung starben von 3306 Ent-
bundenen 32, d. i. 0.; Percent Im Jahre 1848, wo das ganze 
Jahr hinduroh die Chlorwasonungen emsig geübt wurden, star-
ben von 3566 Wöchnerinnen 46, I.„ Percent. An der zweiten 
Abtheilang starben ún Jahre 1848 von 3219 Entbundenen 43, 
d. i. l.M Percent 
Die einzelnen Monate des Jahres 1848 verhielten sich au 
der ersten Abtheilung wie folgende Tabelle zeigt: 
Figure 1. Page from Semmelweis's classic monograph, showing the decline in 
maternal mortality rate in the first obstetrical division of Vienna's 
Allgemeines Krankenhaus, resulting from the introduction of chlorine hand 
washes in May, 1847 [15]. 
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Streptococci both from group A and В continue to be virulent pathogens in 
perinatology. Although no strict separation can be made, group A streptococcus 
predominantly is an exogenous, horizontally transmitted pathogen, being hazardous to 
puerperal women. GBS predominantly threatens neonates following vertical transmission 
from colonized parturients, their intestinal tract serving as an endogenous reservoir. 
In the nineteenth century Semmelweis proved that puerperal fever due to 
horizontal transmission of group A streptococcus could be prevented by scrubbing hands 
with a chlorine solution. The women delivering in the midwives' division of Vienna's 
Allgemeines Krankenhaus served as a control group while the puerperal women from the 
medical students' division in the period before Semmelweis posted his preventive order, 
served as a historical control group. Thanks to the achievements of the nineteenth century 
and the availability of antibiotics in the twentieth century the attention could be shifted 
from 'childbed fever' to life-threatening neonatal infections. At present, antibiotics play a 
major role both in prevention and therapy of neonatal early onset GBS infections. 
Nevertheless, numerous questions remain concerning the best preventive strategy. 
Outline of the thesis 
In our epoch, GBS is recognized as one of the leading causes of life-threatening 
neonatal infections in developed countries. The main objective of the thesis was the 
prevention of neonatal GBS disease from an obstetric point of view. Therefore the 
following studies were carried out. 
The literature on the prevention of neonatal septicemia due to GBS was reviewed 
as a base for the further studies (chapter 2). To establish morbidity and mortality due to 
GBS septicemia/meningitis in our own region, a retrospective study from the neonatal 
intensive care unit of the University Hospital Nijmegen was performed (chapter 3). 
Screening for maternal GBS carriership is an important part of most strategies to 
prevent neonatal GBS disease. In prospective studies, rapid intrapartum screening tests 
were compared to the results of selective GBS cultures, the 'gold standard. ' The 
sensitivity of an enzyme immunoassay test was established in vivo, and an in vitro 
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comparison with another enzyme immunoassay test and two latex agglutination tests was 
also made (chapter 4). The diagnostic performance of the Gram stain for rapid GBS 
screening was established (chapter 5). 
Stimulated by the promising results of a small clinical pilot study [26], the 
potential role of intrapartum vaginal Chlorhexidine disinfection was studied. Analogous to 
Semmelweis' order to scrub hands with a chlorine solution to prevent the horizontal 
transmission of group A streptococcus, intrapartum vaginal disinfection with 
Chlorhexidine might serve as a basic strategy in the prevention of GBS vertical 
transmission. The in vitro activity against perinatal pathogens of Chlorhexidine and two 
other potentially useful antimicobial agents, hexetidine and bacitracin, was studied 
(chapter 6). The main part of the thesis consists of a randomized study of vaginal 
Chlorhexidine disinfection during labor to prevent vertical transmission of GBS (chapter 
7). 
Finally, the findings of this thesis will be integrated and an effort is made to 
formulate some recommendations for a preventive strategy in general practice (chapter 8). 
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Abstract 
Group В streptococcus is the leading cause of neonatal septicemia. Major risk 
factors associated with early onset infection are: heavy maternal GBS colonization, 
preterm delivery, preterm rupture of membranes, prelabor rupture of membranes, 
intrapartum fever, GBS urinary infection, and low levels of maternal serum anti-GBS 
antibodies. 
Screening for maternal GBS colonization, a part of most current preventive 
strategies, can be targeted on all pregnant women or only on those with recognizable risk 
factors, and can be implemented antepartum or intrapartum. A culture in a selective broth 
is the 'gold standard' for detection of GBS colonization. The lower vagina (introïtus) is 
the most suitable site for culturing, with optional addition of an anorectal sample. The 
sensitivity of the available rapid GBS antigen tests for vaginal samples seems too low to 
advocate general use. 
Intrapartum prophylaxis with ampicillin, preferably targeted on GBS colonized 
parturients with risk factors, is the only strategy with established efficacy and safety to 
prevent early onset infection at present. Vaginal Chlorhexidine disinfection during labor in 
all women may offer a contribution to prevention in addition. Late onset GBS disease is 
unlikely to be reduced by these strategies. In the future, immunoprophylaxis may well 
prove to be the most safe and efficacious alternative to prevent GBS septicemia 
irrespective of age of onset, although protection of preterm infants is less likely. 
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Background 
Perinatal infections due to group В streptococcus (Streptococcus agalactiae, GBS) 
cause significant morbidity and mortality and thus a considerable psychosocial and 
economic burden [1-3]. 
Human GBS infection was reported infrequently until the early 1960s but by the 
early 1970s it was recognized as a frequent cause of neonatal and puerperal infections [4-
6]. Gradually GBS infections outnumbered but initially did not replace the existing 
predominant pathogen, Escherichia coli, thereby increasing the overall incidence of 
neonatal septicemia. At present GBS is the leading cause of life-threatening perinatal 
infections in industrialized countries of northern Europe, the United States and Australia. 
Less information is available in developing countries regarding GBS infections because of 
inadequate disease surveillance, reporting systems and laboratory limitations [7]. 
The pathogen 
GBS is one of the species of the genus Streptococcus that can be pathogenic for 
humans. GBS are facultative anaerobic Gram-positive streptococci that produce a 
characteristic appearance of ß hemolysis surrounding colonies when grown on sheep blood 
agar. Some strains will be non hemolytic or a hemolytic. In 1933/1934 Lancefield, using 
serologic techniques, defined two cell wall carbohydrate antigens [8-10]. The group В 
specific antigen differentiates GBS from other serogroups (A, C, D, and G) and a type-
specific antigen allows classification of GBS into four serotypes: la, lb, II, and III. Later 
on the nomenclature has been revised using capsular polysaccharides as type-specific 
antigens and surface proteins (C, X, and R) as additional antigenic markers [11-13]. The 
current classification, which may undergo future alterations, differentiates the following 




In neonates, two patterns of invasive GBS disease have been recognized [17,18]. 
Early onset infection, usually occurring within 24 hours after birth, is characterized by 
fulminant pneumonia, septicemia, shock, and meningitis [1,2]. The presenting signs and 
symptoms are not characteristic for GBS. The late onset type (7 days-3 months after 
birth) is most often insidious and meningitis predominates [1,2]. Early onset infections 
make up two thirds of cases and are usually acquired by vertical transmission from the 
mother's genital tract during birth [1,2]. The late onset type can also be nosocomial or 
community acquired [1,2]. 
The mortality rate of early onset GBS disease ranged from 50 to 70% in early 
studies, and from 13 to 37% more recently [1,2]. This decreased mortality seems to be 
the result of increased awareness of the disease and improvements in supportive therapy 
in neonatal intensive care units. Late onset GBS infection has a reported mortality rate of 
10 to 20% [1,2]. A significant number (from 25 to 50%) of survivors of GBS meningitis, 
whether early or late onset type, have permanent neurologic sequelae [1,2,19]. 
GBS disease in adults occurs with any regularity only in relation to pregnancy and 
less so in elderly, immunocompromised hosts [1,20,21]. Manifestations related to 
pregnancy include chorioamnionitis, early postpartum endomyometritis (particularly after 
cesarean delivery), and cystitis [1,2,22,23]. The organism accounts for 10 to 25% of 
postpartum maternal bacteremia [1,2]. An association between maternal GBS colonization 
and preterm rupture of membranes and/or preterm delivery has been reported, although 
the information so far is conflicting and evidence for a causal relationship is still lacking 
[1,23-29]. This morbidity was found to be associated with GBS bacteriuria in particular 
[30,31], but recent data show an association between elevated levels of urinary antibodies 
to GBS (and E. coli), rather than positive urine cultures, and preterm delivery [32]. 
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Epidemiology 
Asymptomatic maternal urogenital GBS colonization occurs in 4 to 40% (usually 
about 20%) of pregnant women, depending on the population studied, the culture 
technique, and the location and number of sites cultured [1,2,33-36]. Carrier rates are not 
higher compared to the nonpregnant state and fairly constant during the three trimesters 
[1]. In infants born of GBS carriers vertical transmission ranges from 30 to 75% (mean, 
50%), and this is increased in the presence of a high genital inoculum [1,2,36-39]. Most 
often contamination occurs following passage of the infant through the birth canal. 
However, in utero colonization by the ascending route with ruptured, or occasionally with 
intact membranes, has been clearly documented [2,40]. Despite high prevalence rates for 
vertical transmission, the neonatal attack rate for early onset infection ranges from 1.3-
3/1000 live births, and from 1-1.7/1000 live births for late onset infection only [2]. 
Although carrier rates appear to be similar in the United States and northern Europe, 
prospective studies have shown a much higher (about 10 times) incidence of early onset 
septicemia in the United States than in most European countries, including Britain [41-
43]. 
The GBS serotype distribution is similar for mother/neonate pairs [1,36]. 
Asymptomatic colonized parturients show a distribution that is divided evenly among the 
three major serotypes: I, II, and III [1]. For neonates with early onset infection without 
meningitis, the serotype distribution of isolates parallels that of asymptomatically 
colonized mothers or infants [1]. However, type III strains have been isolated from most 
newborns (80%) with early onset infection with meningeal involvement. This serotype is 
also responsible for 93% of late onset infections regardless of clinical expression [44]. 
Risk factors associated with early onset infection 
Heavy genital colonization is associated with a higher rate of vertical transmission 
and an increased risk for early onset neonatal septicemia [1,2,45-48]. Other major 
perinatal risk factors for GBS septicemia include preterm ( < 3 7 weeks) delivery and 
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related low birth weight, preterm rupture of membranes, prelabor rupture of membranes 
( > 12-18 h before delivery), intrapartum fever, and GBS urinary infection [1,2,47,49,50]. 
The latter is considered to be a likely indicator of heavy genital colonization. Infants of 
mothers with low levels of serotype-specific antibody to the GBS capsular polysaccharide 
in the serum are also at risk [51,52]. 
The presence of one or more of these major risk factors in a GBS carrier is 
associated with a 5-fold to 35-fold increase in risk for neonatal septicemia in her 
offspring. The overall attack rate of 1.3-3/1000 live births increases to 1/100 in colonized 
neonates and to 1/25 if there are additional major risk factors [53], which are present in 
about 4% of the obstetrical population [54]. Minor risk factors include multiple births, 
congenital anomalies, prolonged labor, assisted delivery, age less than 20 years, and, 
perhaps, black race and diabetes mellitus [1,2]. 
Special attention is warranted for the woman with a previous child that suffered 
invasive GBS disease. Although this may not be a well established risk factor, the 
situation is highly emotionally charged and some form of intervention seems indicated. 
It is important to realize that the above mentioned risk factors are only 
infrequently associated with late onset disease [1]. In preventing early onset infections 
however, a beneficial policy may be obtained based solely on a knowledge of risk factors, 
even if GBS carrier status is unknown. 
Screening 
GBS carriership is a prerequisite for early onset GBS disease, and screening 
pregnant women is part of most preventive strategies, although the optimal method 
remains controversial. The 'gold standard' for the diagnosis of GBS colonization is 
culture in a selective broth [1,2]. Such medium usually contains Todd-Hewitt broth with 
or without sheep red blood cells (5%) and includes antimicrobial agents, such as nalidixic 
acid and gentamicin or Colistin, that inhibit the growth of other microorganisms [55]. Use 
of non selective media diminishes the detection by 50% or more [33]. 
The more samples (anorectum, vagina, cervix, urine) are cultured, the higher the 
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colonization rate that will be found. The lower gastrointestinal tract is probably the 
principal reservoir for GBS [1,2,35,36,56]. Although isolation rates are higher from the 
anorectum [36], and no one site has shown to be exclusively predictive of perinatal 
infection, genital colonization has been found to be associated with a higher frequency of 
transmission than anorectal colonization. In view of the finding that genital tract isolation 
rates are reported highest from the lower vagina (introïtus) and lowest from the cervix 
[1,2,36], the lower vagina seems the most suitable site for screening, with optional 
addition of an anorectal sample. To reduce costs, both sites can be sampled using two 
swabs inoculated into a single tube of broth, or with one swab, swabbing first the vaginal 
introïtus and then the anorectum. 
Selection of women at risk for early onset GBS disease in their offspring is best 
made during labor, as carriership may be intermittent or temporary rather than permanent 
[1,2,35,36]. The predictive value of antenatal cultures for GBS colonization at delivery 
varies inversely with the interval between culture and delivery. Half or more of antenatal 
carriers may become culture-negative at the time of parturition [36,41,57,58]. A major 
limitation of intrapartum screening with culture is that the results usually take too long 
(24-48 hours) to be of clinical importance. Therefore, several 'rapid' methods have been 
developed and evaluated in the last two decades. Most of these techniques appeared to be 
either insensitive or complicated to perform and take too long for implementation. Really 
rapid tests (result within 1-2 hours), which include latex agglutination and enzyme 
immunoassay, are based on the demonstration of the group-specific polysaccharide antigen 
of GBS in vaginal samples. Although these tests are quite specific, conflicting results 
about the sensitivity have been reported, as well as some logistical problems [59-74]. 
Yancey et al. reported the use of a DNA probe [75]. The mean time required to perform 
the assay, including a growth amplification step, was more than 4 hours, while overall 
sensitivity was still not optimal. The Gram stain has also been evaluated as rapid GBS 
screening method but is neither recommended because of low diagnostic performance [76-
82]. 
All screening methods yield more accurate results in persons with higher GBS 
counts. Some authors take the view that identification of heavily colonized rather than all 
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colonized parturients may be adequate, while others point to the experience that 20-50% 
of colonized women will be missed and even scant maternal colonization can result in 
transmission of GBS to the neonate [58,59,73,79,83]. In conclusion, the cunent 
sensitivity seems too low to recommend rapid GBS screening tests to be generally 
instituted as the keystone of large-scale preventive protocols. 
Preventive strategies 
Strategies to prevent GBS neonatal septicemia remain a challenge for both 
obstetricians and pediatricians. No consensus exists on the best approach to prevent early 
onset GBS infection [54,84]. Strategies for primary prevention aim at reducing maternal 
(and thus neonatal) colonization, or aim at protective levels of GBS antibodies in the fetus 
or newborn. Primary prevention cannot be sharply separated from secondary prevention 
(early treatment with antibiotics and/or passive immunotherapy) in clinical practice, 
because the onset of GBS disease before clinical symptoms are evident, whether in utero 
or after delivery, cannot be easily recognized. Established clinical chorioamnionitis and 
early onset GBS disease in the newborn are treated with antibiotics and supportive therapy 
(and experimental passive immunotherapy). These interventions are forms of tertiary 
prevention, preventing deterioration and/or permanent sequelae. Preventive strategies 
suggested in the literature are summarized in table 1, and can be divided in two basic 
approaches: chemoprophylaxis and treatment, and immunoprophylaxis and treatment. 
There seems to be fairly high agreement that chemoprophylaxis with antibiotics need to 
be focused only on carriers with recognizable risk factors, as it is accompanied by 
considerable costs and a risk of adverse reactions and bacterial resistance. Using a 
selective approach will cause missing of some cases of neonatal septicemia and no single 
strategy will turn out to be a panacea. Therein lies a dilemma. Any specific prevention 
protocol will be depending on a number of factors, including the background GBS 
carriage rate in a population, the proportion of patients with perinatal risk factors and 
local availability of screening facilities. 
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Table 1. Primary,1 secondary,11 and tertiaryni prevention of neonatal septicemia due 
to GBS reported in the literature. 
I) Chemoprophylaxis and treatment 
A) antibiotics: antepartum screening + antepartum prophylaxis1™ 
antepartum screening + intrapartum prophylaxis1·"" 
intrapartum screening + intrapartum prophylaxis1™ 
ante/intrapartum treatment of clinical chorioamnionitis111 
neonatal prophylaxis and treatment1·*10·1" 
B) Chlorhexidine: intrapartum vaginal disinfection1 
II) Immunoprophylaxis and treatment (experimental) 
A) passive: intrapartum prophylaxis1™ 
neonatal prophylaxis and treatment1·™111 
B) active: vaccination before/during pregnancy1 
Antepartum screening and antibiotic treatment of carriers is generally unsuccessful 
[85-87] due to a high percentage of reacquisition of GBS from the lower gastrointestinal 
tract or from venereal transmission. Starting this strategy at 38 gestational weeks will 
diminish the problem of reacquisition but misses the group at greatest risk, women 
delivering preterm [88]. However, antepartum oral antibiotic therapy seems indicated for 
the woman with GBS bacteriuria [53,89] and can also be considered for the woman with a 
previous child with GBS disease that was born preterm. 
Successfull interruption of vertical transmission of GBS has been achieved by the 
administration of intravenous ampicillin during labor [90]. To date, intrapartum antibiotic 
treatment of (heavily) colonized parturients with one or more risk factors, whether 
combined with antepartum or intrapartum screening, is the most rewarding approach. It is 
the only strategy whose efficacy and safety is supported by a number of randomized 
controlled trials [88,91-94]. These trials and some other studies report a major reduction 
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in neonatal GBS colonization, early onset GBS septicemia and neonatal deaths from 
infection [58,95-97]. Intravenously administered ampicillin, amoxycillin or penicillin G 
are the drugs of choice, because of their safety, their low degree of serum protein binding 
and activity against common perinatal pathogens in addition to GBS [92]. Usual regimens 
start (ideally at least 4 hours before delivery) with 2 g ampicillin, with 1 to 2 g every 4 to 
6 hours until delivery [53,89,98,99]. Ampicillin is rapidly transported across the placenta, 
resulting in therapeutic levels in the fetus and amniotic fluid within a few hours, which 
last in the neonate for about 8 hours following delivery [2,100,101]. Penicillin-allergic 
women may be given erythromycin, a first generation cephalosporin, or clindamycin, 
which also provide good coverage [2,53,89,98,99]. 
Numerous questions arise concerning the evaluation and treatment of infants born 
of GBS carriers treated intrapartum with antibiotics. False-negative blood cultures occur 
in symptomatic neonates born of mothers receiving prophylaxis. Scant information is 
available from clinical studies, but empiric recommendations can be formulated, based on 
assessment of the infant's risk of sepsis as indicated by clinical manifestations and 
gestational age [89,98]. If the newborn is a healthy appearing term baby, therapy need not 
be given. If the neonate appears ill or is at < 34-37 weeks gestation, ampicillin is given 
and a complete blood count, blood culture, and chest radiograph are done. Therapy 
should be continued for 3 or 5 to 10 days, the latter being for infants who appear ill or 
have an abnormal laboratory test. The decision about continuing ampicillin in the mother 
is based on the likelihood of maternal disease [98,99]. 
In cases of maternal pyrexia on the basis of clinical chorioamnionitis antibiotics 
should be started empirically and without delay, prior to the availability of culture results 
and regardless of GBS carriership. A broad spectrum approach is required, preferably 
with ampicillin plus an aminoglycoside, as maternal infections tend to be polymicrobic in 
nature with aerobic and anaerobic bacteria present [2,53,98]. 
Single-dose penicillin prophylaxis in neonates at birth is ineffective at preventing 
bacteremia or reducing the mortality rate [95,102-105], probably because the majority of 
neonates with early onset GBS septicemia is already bacteremic at or within 1-6 hours of 
birth [50,105]. An increase in septicemia with penicillin-resistent organisms, resulting in a 
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higher mortality rate from infection, has also been reported [104]. While penicillin-
resistance occurs, newborns do not develop penicillin- or ampicillin-allergy. 
The most common pediatric recommendation for established (GBS) neonatal 
infection is an ampicillin-aminoglycoside combination [1,2]. Ampicillin is capable of 
crossing the meninges into the cerebrospinal fluid. Although GBS are resistant to 
aminoglycosides in vitro, addition of one of the penicillins results in a significant 
synergistic action in vitro and in vivo [2,106,107]. Therapy should also be routinely 
considered for the asymptomatic sibling of a twin with early onset septicemia [1,108]. 
Vaginal disinfection with Chlorhexidine [109-114] during labor has been proposed 
to prevent GBS vertical transmission and subsequent neonatal early onset GBS disease 
[115,116]. It is a simple, cheap and safe alternative for antibiotic prophylaxis, without 
risk for development of bacterial resistance and only a very low risk for adverse 
reactions. Moreover, as compared to antibiotic therapy, Chlorhexidine disinfection would 
obviate the necessity of screening and selection. In 1992, Chlorhexidine disinfection 
during labor was reported to reduce excess neonatal morbidity associated with GBS [117]. 
However, the effect of vaginal disinfection with Chlorhexidine on vertical transmission 
had not yet been investigated in a randomized trial. 
Immunoprophylaxis refers to induction of protective humoral immunity by passive 
or active immunization, and seems a promising strategy although it is not yet clinically 
applicable [1,7,118-1201. 
Administration of anti-GBS hyperimmune globulin or monoclonal antibodies to 
colonized pregnant women in labor might prevent maternal and neonatal disease [121]. 
Passive immunization with intravenous immunoglobulin (IVIG) administered to 
neonates has been shown to reduce the incidence of bacterial sepsis and resulting 
mortality [122]. Currently available preparations yield a level of specific antibodies to 
GBS antigens that theoretically is too low to be protective, unless patients are volume 
overloaded [123]. Therefore, other investigators have focused on preparation of 
hyperimmune and specific monoclonal formulations to overcome the low titers of anti-
GBS antibody in standard formulations [124]. Passive immunization is expensive and 
cannot be considered standard therapy at present. However, it could be a useful adjuvant 
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to treatment in neonates, especially those born at less than 33-34 gestational weeks, with 
known infection [1,125]. 
As with many other lethal diseases of the past, prevention of GBS infections can 
be approached as a public health issue through active immunization with a vaccination 
protocol [1,7,119,126]. Although protective levels of maternal serum antibodies do not 
prevent maternal perineal colonization, there is substantial evidence that they are 
protective against neonatal infection [51,127-129]. Unfortunately, such levels are absent 
in 80-90% of women of childbearing age 1130]. Development of an immunogenic, 
inexpensive and nontoxic vaccine theoretically offers the most efficacious means to 
prevent neonatal GBS infections. In contrast to chemoprophylaxis, this approach might 
prevent not only early onset disease, but also late onset disease. 
In order to design a vaccine, a framework of different steps must be followed, 
starting with the identification of a relevant antigen. Among the antigens for candidate 
vaccines are native bacterial type-specific polysccharides (e.g. type III GBS 
polysaccharide is considered to be a virulence factor), conjugated polysaccharides and 
derivative oligosaccharides (coupling to a carrier protein such as tetanus toxoid enhances 
the immunogenicity), and С proteins [119]. Preferably, the vaccine would need to 
stimulate antibody against all serotypes of GBS. Therefore, the polysaccharide and С 
protein formulations need to be polyvalent. The characterization of a universal antigen, 
permitting single antibody recognition, is a yet theoretical option for a monovalent 
vaccine [131]. 
The antibodies resulting from active immunization have been shown to have a role 
in the integrated immune response, interacting with both polymorphonuclear leukocytes 
and serum complement to provide enhanced killing of GBS by opsonization and 
phagocytic uptake. This immune response must be expressed at the correct site. In 
preventing early onset GBS infections this means that an IgG response is important, 
because transplacental passage of antibodies is required. Unfortunately, placental transfer 
of anti-GBS IgG is limited before 34 weeks gestation [52,128,129,132]. Subsequently, 
preterm neonates will benefit proportionally less from maternal vaccination, while it is 
hypothesized that their immature complement system already predisposes them to severe 
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(GBS) infections. 
Active immunization, whether or not limited to antibody-deficient women, could 
be targeted on pregnant women during their second to third trimester or, alternatively, all 
women in the childbearing years. Despite the problems of non-responders and limited 
protection of preterm neonates, vaccination may well prove to be a promising future 
strategy. 
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Abstract 
Retrospectively, morbidity and mortality of neonatal early onset group В 
streptococcal (GBS) infection were established in a tertiary care hospital. Risk factors and 
prognostic factors were determined. 
Between 1985 and 1993, 78 patients with early onset GBS disease were identified. 
The overall mortality rate was 23%. In 60 of 73 cases (82%) at least one of the 
investigated risk factors was present. Low birth weight was not an independent risk 
factor. Outcome of 44 of 60 survivors (73%) at the age of at least one year was obtained. 
Almost 30% of them had sequelae. The most important were spastic disorders and 
delayed psychomotor development. In 42% of patients with symptoms of GBS-infection 
within six hours after birth, sequelae occurred. There were no sequelae among patients 
with symptoms occurring after 6 hours. All 9 severely brain damaged infants showed 
symptoms shortly after birth. Mortality and adverse outcome rate were higher in infants 
with low gestational age or low 5 minute Apgar scores. Early treatment resulted in less 
mortality, but did not reduce sequelae. 
GBS-sepsis still causes significant mortality and leaves a substantial number of 
survivors damaged. Alertness to GBS-infection, even in the absence of risk factors, 
remains crucial for early treatment and good outcome. 
46 
Retrospective study earfy onset GBS infection 
Introduction 
The group В streptococcus (GBS, Streptococcus agalactiae) has been one of the 
leading causes of neonatal infections in the western world since the early 1970s [3,5,8]. 
The incidence of GBS disease varies over different countries, but appears to be constant 
over the last fifteen years [6]. GBS infections can have an early or a late onset, each of 
which is associated with a distinct clinical picture. 
Early onset disease (EOD) occurs in the first seven days of life and is usually 
caused by vertical transmission from the birth canal. Of all pregnant women, 4-40% are 
colonized with GBS, depending on the population, the sample sites and culture methods 
[4,6,9,12]. The rectum is the main reservoir, which often contaminates the vagina [9,11]. 
Transmission during labor occurs in 28-73%, but only 1-5% of colonized infants develop 
EOD [2,12]. The incidence amounts to 0,7-3,7/1000 live births [6]. Low birth weight, 
preterm delivery, prolonged rupture of membranes, signs of intrapartum infection, heavy 
colonization and multiple birth have been noted to be risk factors for EOD [3,8]. Infants 
of mothers with low levels of serogroup-specific antibodies against GBS also have a 
higher risk to develop disease [6]. The most common manifestation of EOD is respiratory 
disease, which may resemble the clinical picture of hyaline membrane disease [14]. Other 
manifestations are sepsis, meningitis, jaundice and lethargy, but the infection may be 
asymptomatic as well [5]. The prognosis of EOD seems to have improved over the years: 
older studies report mortality rates of 50-80%, while rates of 13-37% are reported more 
recently [6]. 
Late onset disease (LOD) occurs after seven days of age and is caused by both 
vertical transmission and nosocomial contact [3,6]. The incidence of LOD amounts to 
0,8-1,9/1000 live births [3,6]. LOD more often presents as meningitis (85%) and sepsis, 
as well as local infections, including osteoarthritis, urinary tract infection, pneumonia and 
cellulitis [6,14]. LOD has a mortality rate of 0-23% [3,14]. Unfortunately, approximately 
50% of GBS-meningitis survivors will develop neurological damage [7]. 
In this study, all patients with neonatal GBS infection admitted to the neonatal 
intensive care unit of our hospital between 1985 and 1993 were reviewed to verify the 
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tendency of decreasing mortality described by others, as well as to establish the long-term 
outcome in relation to prognostic and risk factors. 
Material and methods 
The data of all patients with a GBS-positive blood or cerebrospinal fluid culture, 
as well as patients with clinical symptoms and either positive superficial (ear, nose, 
throat, umbilicus) or maternal cervical culture were reviewed. 
Maternal fever >38°C, leukocytosis ( > 1 6 χ lO'/l) and/or tachycardia of > 160 
beats per minute were regarded as intrapartum signs of infection. Gestational age, 
duration of membrane rupture, birth weight, sex, 5 minute Apgar score, clinical and 
laboratory findings, treatment and clinical outcome at the age of at least one year were 
recorded. To determine outcome, data from the latest visit to the out-patient clinic were 
used or a questionnaire was sent to the parents. 
Results 
Frequency and mortality 
EOD was diagnosed in 78 patients (41 males, 37 females). In 61, there were both 
symptoms and a positive blood culture. A positive blood culture without symptoms was 
found in 14 patients. Three patients had no positive blood culture but clear symptoms; 
two of them were treated with antibiotics before culturing. In 8 of the 78 patients other 
microorganisms were cultured from blood as well: Escherichia coli (3), Staphylococcus 
aureus (3), viridans streptococci (1) and Klebsiella pneumoniae plus Proteus mirabilis (1). 
All these 8 patients had symptoms of infectious disease. All 5 patients in whom 
cerebrospinal fluid cultures were GBS-positive died. 
In figure 1 the distribution of cases and mortality over the years is shown. The 
number of newborns with EOD varied from 4 to 14 per year. Overall mortality rate was 
found to be 23%. 
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Figure 1. Number of neonates per year with GBS early onset disease (EOD) and 
related mortality. 
LOD occurred in 4 patients (2 males, 2 females). Two patients, both with 
meningitis, died and the other 2 survived without sequelae. They were not further 
included into this study. 
Clinical presentation 
Fourteen patients with EOD (18%) had a positive blood culture without clinical 
symptoms. In all remaining 64 cases of EOD, manifestations occurred within the first 48 
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Table 1. Most important risk factors* in 78 cases of neonatal GBS early onset 
disease and related mortality. 
Gestational age 
Duration of ruptured membranes 
Intrapartum signs of infection*'1' 























































* Most important known risk factors from the literature: preterm delivery (<37 weeks), prolonged rupture 
of membranes (>24 hours before delivery), and intrapartum maternal fever. ** Maternal temperature 
ä38°C, and/or maternal leukocytosis > 16 χ IC/l, and/or fetal tachycardia > 160 beats/min. 
hours. These were a variety of combinations of respiratory disease (53%), persistent 
pulmonary hypertension (16%), shock (13%), convulsions (12%), hyperbilirubinemia 
(9%), signs of necrotizing enterocolitis (8%), apnoea and bradycardia (5%), hypotonia 
(5%), cyanosis (3%) and oedema (3%). Laboratory findings consisted of leukocytosis, 
thrombopenia, leukopenia, hyperglycemia, metabolic acidosis and elevated C-reactive 
protein. 
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Treatment 
Treatment consisted of intravenous administration of a ß-lactam antibiotic 
(ampicillin, amoxicillin or a third generation cephalosporin) in combination with an 
aminoglycoside (mostly gentamicin). In some cases, patients were treated with a 
penicillin-derivative only, including amoxicilline/clavulanic acid. In a number of cases, 
administration of antibiotics was changed from intravenous into oral after a few days. 
Risk factors 
The presence of risk factors and related mortality were reviewed in all patients 
with EOD (table 1). Half of the patients had a gestational age below 37 weeks. Of all 
fatal cases, 61 % was below 37 weeks. Remarkably, no mortality was found in the group 
between 34-37 weeks. Thirty-two patients (41 %) had a birth weight below 2500 g, and 
35% of them died. GBS-infection was not related to fetal growth retardation, since the 
population showed a normal distribution over the birth weight percentiles (figure 2) [10]. 
Thirty-eight patients had a birth weight below and 40 above the 50th percentile. 
Prolonged rupture of membranes (>24 hours) was present in at least 50% of all 
cases; duration was unknown in 9%. Signs of intrapartum infection were present in over 
one third of all cases (37%). 
Data about risk factors were incomplete in 10 patients; however, 5 of them had at 
least one risk factor. Therefore, at least one risk factor was present in 82% of the cases 
(60/73). This leaves about one out of five patients without any of the three risk factors 
studied. 
Follow-up 
In 44 of the 60 survivors (73%) long term follow up data of at least one year were 
available. Fourteen parents did not return the questionnaire, two families had moved and 
could not be located. Thirty of these 44 patients (68%) had no sequelae. Unfortunately, 
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Figure 2. Number of neonates with GBS early onset disease (EOD) and related 
mortality by birth percentile [10]. 
one of them suffered from Hemophilus influenzae meningoencephalitis at the age of 10 
months, which left him severely handicapped. Three patients suffered from spastic 
tetraplegia, one of them also showed mental retardation. Two patients had a combination 
of spastic diplegia and congenital strabismus. Logopedia was indicated for 3 patients, one 
of them never had symptoms of GBS-sepsis. Neuromotor developmental delay was 
present in 4 patients, one of which also had problems with speech and social 
development. One patient had behavioral problems and EEG disturbances and one had 
absences at a very young age. 
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Table 2. Presence of some parameters and related outcome of 78 neonates with GBS 
early onset disease. 
Gestational age 
Duration of mptured 
membranes 
Intrapartum signs of 
infection* 
Mode of delivery 
5 min Apgar score 
Onset of symptoms** 
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* Maternal temperature a>38°C, and/or maternal leukocytosis >I6 χ 109/], and/or fetal tachycardia >160 beats/nun ** 14 neonates 
with positive GBS blood culture did not develop clinical symptoms as early treatment was started because of signs of infection in the 
mother and/or laboratory findings 
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Table 2 shows the outcome in the 78 patients with EOD. Mortality was higher in 
neonates with lower gestational age (<34 weeks: 39% vs 2:34 weeks: 14%) with more 
sequelae among the survivors with known outcome (44% vs 25%). In neonates with a 
gestational age of >37 weeks, the mortality rate was 19% and sequelae were found in 
24% of survivors with known outcome. Of the 32 patients born within 24 hours after the 
membranes had ruptured 13 died (41%), and 6 of the 13 patients with known outcome 
had sequelae (46%). Thirty-nine patients were born after prolonged rupture of 
membranes, 4 (10%) died, and 7 of 27 patients with known outcome (26%) had sequelae. 
The presence of intrapartum signs of infection did not increase the mortality rate, but 
doubled the frequency of sequelae in survivors with known outcome (47% vs 23%). 
Survivors with known outcome, born by caesarean section, had more sequelae (58%) than 
those born by instrumental or spontaneous delivery (27%). Among neonates with a 5 
minute Apgar score <7 the mortality rate was higher (31%) than in the group with a 
score ^ 7 (21%). Two thirds of survivors in the low Apgar score group had sequelae 
versus 23% in the high Apgar score group. 
Eleven of 26 surviving patients (42%) with symptoms of GBS-infection within 1 
hour after birth had sequelae. Nine of them were severely damaged. Two of 5 surviving 
patients with symptoms between 1 and 6 hours after birth had (minor) sequelae. Among 
the 4 surviving patients with symptoms occurring after 6 hours and known outcome, no 
sequelae were found. Early treatment, within 1 hour after birth, resulted in less mortality, 
but did not influence the outcome in survivors. All patients with spastic disorders were 
preterm. Three of 4 patients with neuromotor developmental delay were over 37 weeks of 
gestational age. All 8 patients with positive cultures of other microorganisms besides GBS 
survived. 
Discussion 
To reduce adverse outcome of early onset GBS-disease, early identification and 
treatment is essential. We could not prove any decrease in mortality rate of infants with 
EOD during the last 10 years in our population. Prematurity, prolonged rupture of 
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membranes and antenatal signs of infection were confirmed as risk factors. Birth weight 
was not found to be an independent risk factor, but reflected gestational age. Absence of 
risk factors does not exclude EOD, since almost 20% of patients had none of the studied 
risk factors. In all cases of neonatal disease of unknown origin, GBS-sepsis should be 
included in the differential diagnosis. 
As 14 patients were treated because of GBS-positive blood culture before any 
symptoms developed, their inclusion in the study can be debated. The possibility of 
contamination of blood cultures collected from a peripheral vene, and especially from 
umbilical vessels or catheters, cannot be totally excluded [13]. If they would not have 
developed EOD without treatment, their inclusion would be incorrect. Then, the 
prognosis of EOD in this study would be worse. 
The outcome in the group of neonates born after prolonged rupture of membranes 
was not unfavorable, probably due to a higher degree of alertness to GBS-disease. 
Patients born by ceasarean section had more sequelae, which can probably be explained 
by fetal distress being the reason for emergency caesarean section. 
It is difficult to predict outcome of GBS-sepsis in individual cases. Sequelae cannot 
always be exclusively related to GBS-sepsis, especially in preterm infants. Outcome is 
also determined by the occurrence of other disorders such as cerebral hemorrhage and 
periventricular leucomalacia. Prematurity and sepsis are both risk factors for 
intraventricular hemorrhage and periventricular leucomalacia, while maternal GBS 
colonization has been associated with preterm birth [1]. In our population, all patients 
with spastic disorders had intraventricular hemorrhage or periventricular leucomalacia, 
and all were premature. 
In conclusion, outcome of GBS-sepsis is influenced by many factors, including 
gestational age, onset of symptoms and time of treatment, severity of respiratory and 
circulatory disease and the occurrence of complications related to prematurity. Alertness 
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Abstract 
The sensitivity of intrapartum screening for group В streptococcal (GBS) 
colonization was evaluated and 4 rapid GBS antigen tests were compared in vitro. 
Two swabs of the lower vagina of 769 parturients were taken; one swab was 
cultured, the other was frozen at -70°C until antigen testing with the Group В Strep Test 
(Quidel) of the culture positive samples was performed. The Quidel test was then 
compared with 3 other rapid GBS antigen tests in vitro: Wellcogen Strep В (Wellcome 
Diagnostics), Slidex méningite Strepto В (bioMérieux) and ICON Strep В (Hybritech). 
The supernatant of 29 GBS cultures in Todd-Hewitt broth was tested in bacterial 
concentrations of 10*, 107, and 108 Colony-Forming Units (CFU)/ml, respectively. 
Lower vagina GBS carrier rate was 13.4% (103/769) and heavy colonization 
(growth density 3 and 4 on blood agar plates) was found in 5.2% (40/769). The Group В 
Strep Test detected 11% (11/103) of GBS carriers, with a sensitivity for heavy 
colonization of 25% (10/40). In vitro none of the tests scored positively with a 
concentration of 106 CFU/ml, while with 107 CFU/ml the enzyme immunoassay tests 
(Quidel, Hybritech) were more sensitive (McNemar test, ρ < 0.05) than the latex 
agglutination tests (Wellcome Diagnostics, bioMérieux). 
Although in vitro the enzyme immunoassay tests are more sensitive than the latex 
agglutination tests, sensitivity in vivo is too low to recommend the use of rapid antigen 
tests for general screening. 
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Introduction 
Group В beta-hemolytic streptococcus (GBS, Streptococcus agalactiae) is 
recognized as a major cause of neonatal sepsis and accounts for 10% to 25% of 
postpartum maternal bacteremia [1,2]. Invasive neonatal group В streptococcal infections 
present themselves either as early (usually within 24 hours) or late (after 7 days) onset 
disease. Two thirds of cases are early onset infections, usually acquired by vertical trans­
mission from the mother's genital tract. Asymptomatic vaginal colonization with GBS 
occurs in 4% to 40% (usually about 20%) of pregnant women, depending on the 
population studied and culture technique used. The highest genital tract isolation rates are 
reported from the lower vagina (introïtus) and lowest from the cervix [1,2]. In infants 
born to colonized mothers vertical transmission has been shown to range from 40% to 
70% (mean 50%), the risk being greater in the presence of a high genital inoculum. 
Despite high prevalence rates for vertical transmission, the incidence of early onset GBS 
infection is only 1-10/1000 live births. However, mortality is significant, ranging from 
50% to 70% in older studies and from 13% to 37% more recently [1]. About half of the 
infants who survive GBS meningitis are left with permanent neurologic sequelae. 
There is no consensus on the best approach to prevent early onset GBS infection. 
Although conflicting results have been reported, single-dose penicillin prophylaxis in 
infants cannot be recommended [3-5]. Several studies have demonstrated that intrapartum 
antibiotic therapy (ampicillin, penicillin G) reduced vertical transmission of GBS [6-9]. 
An alternative approach to chemoprophylaxis is vaginal Chlorhexidine disinfection during 
labor [10-12]. Infants of mothers with low levels of antibodies against GBS are at risk 
and a program of active immunization aimed at pregnant women would probably be most 
efficacious in controlling perinatal GBS disease. However, an effective vaccine is not 
available at present [13]. 
For the time being, intrapartum chemoprophylaxis in selected high risk parturients 
is the method of choice for preventing GBS infections. Apart from other risk factors, 
GBS carrier state in pregnant women plays a crucial role. A selective culture is the "gold 
standard" for intrapartum screening but the results usually take too long to be of clinical 
61 
Chapter 4 
importance. Therefore, several "rapid" GBS screening methods have been developed and 
evaluated in the last two decades. Most techniques have been shown to be either insensiti­
ve or complicated to perform and take too long for implementation. Among the really 
rapid tests (result within 2 hours) are latex agglutination and enzyme immunoassay. These 
rapid antigen detection tests appear to be quite specific but the question still remains 
whether they are sensitive enough to be instituted as the keystone of a large-scale 
preventive protocol. 
The purpose of this study was to evaluate the sensitivity of intrapartum GBS 
screening and to compare four rapid group В streptococcal antigen tests in vitro. 
Materials and methods 
Collection of material 
The study took place at two hospitals in the city of Nijmegen, The Netherlands. 
The protocol, which was part of a bigger study, was approved by the ethics committees 
of both hospitals and informed consent was obtained from the participating women. 
Two swabs of the lower vagina of 769 parturient women whose GBS carrier state 
was unknown were taken in a fixed order. The first, rayon tipped plastic swab, was 
stored at 4°C and frozen at -70°C within 24 hours. The second, cotton tipped wooden 
swab, was put in Todd-Hewitt broth, stored at 4°C and plated semiquantitative^ on 5% 
defibrinated sheep blood agar within 24 hours. The blood agar plates were incubated for 
48 hours at 37°C. After plating, the swabs were put in a selective enrichment broth 
consisting of Todd-Hewitt broth with 15/tg nalidixic acid per ml and 8¿tg gentamicin per 
ml, inhibiting the growth of Gram-negative Enterobacteriaceae and other bacteria in the 
normal genital tract flora that could interfere with the recovery and identification of GBS. 
After overnight incubation at 37°C the swabs were plated on blood agar and incubated at 
37°C for another 24 hours. Confirmation of identified GBS was done by the CAMP-
reaction and resistance to bacitracin on Casman medium base with 5% defibrinated sheep 
blood and if necessary agglutination with Streptex latex suspension (Wellcome Diagnos-
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tics). 
After 48 hours' incubation the growth density (1, 2, 3, or 4) on the directly plated 
blood agar plates was determined. If GBS were only isolated from the enrichment broth, 
this was scored as growth density 0. 
Determination of sensitivity 
When all culture results were available, the frozen swabs of parturients with 
positive GBS culture were defrosted and tested with the Group В Strep Test (Quidel), an 
enzyme immunoassay. The tests were always performed by the same technician in accor­
dance with the manufacturer's instructions. The swab samples were extracted with 
extraction reagents and the extracted fluid samples transferred to a test cartridge contai­
ning a nitration membrane coated with rabbit polyclonal antibodies to GBS. Filtration 
occurred by gravity and GBS antigen present in the sample bound to the antibodies on the 
surface of the membrane. Antibody-enzyme conjugate, wash solution, and an enzyme sub­
strate solution were added to develop and stabilize the test result. A positive result was 
indicated by a distinct blue circle on the test cartridge membrane, a negative result by a 
negative sign without a blue circle. A positive GBS control was included in the kit. The 
entire test could be performed in less than 10 minutes. 
Refrigeration of the samples does not affect test results because the enzyme 
immunoassay test identifies bacterial antigens regardless of the presence of live 
organisms. Moreover, the GBS is resistant to freezing and survives well [14]. Never­
theless, to detect any possible loss of antigen-expressivity by freezing the swab, we 
compared freshly obtained and pre-frozen specimens. For this purpose 3 identical rayon 
tipped swabs were taken from the lower vagina in 10 known GBS carrier women. One 
swab was cultured as mentioned above, one was tested immediately, the third being 
frozen at -70°C and tested later. 
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Table 1. Results of lower vaginal culture and Group В Strep Test (Quidel) in 103 





No. of swabs positive by: 













Total 103 (13.4) 11 l i t 
* Percentage of total cultures; t sensitivity for heavy colonization (growth density 3 and 4): 25%, 95% 
confidence interval 12-42%; | 95% confidence interval 5-19%. 
In vitro comparison of the antigen tests 
To compare 4 different rapid group В streptococcal antigen tests we tested the 
supernatant of 29 GBS cultures in Todd-Hewitt broth in 3 different bacterial concentra­
tions with each of the tests. The strains used were 28 randomly chosen patient strains 
from our frozen stock and 1 American Type Culture Collection strain (ATCC 13813). 
The three concentrations tested contained 106, 107, and 108 Colony-Forming Units per ml 
(CFU/ml). For each test 50/tl of the solutions was used. A growth density 2 on the blood 
agar plate corresponded to 106 CFU/ml, while growth densities 3 and 4 corresponded to 
107 and 108 CFU/ml respectively. Two latex agglutination tests were performed, namely 
the Wellcogen Strep В (Wellcome Diagnostics) and the Slidex méningite Strepto В (bio-
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Mérieux) and two enzyme immunoassays, the Group В Strep Test (Quidel) and the ICON 
Strep В (Hybritech). Tests were performed following the manufacturer's instructions by 
the same technician. A positive control was included in all test kits. Test results were 
scored as negative, slightly positive, positive or clearly positive. 
Statistical method 
The McNemar test for paired samples was used to compare the results of the tests. 
Results 
Table 1 shows the results of vaginal cultures and the Group В Strep Test (Quidel). 
The cultures of 103 of the 769 laboring women revealed GBS, the GBS carrier rate in the 
lower vagina being 13.4%. Growth densities (0, 1, 2, 3, and 4) on blood agar plates 
among carriers were distributed as shown in the table. Heavy colonization (growth density 
3 and 4) was found in 5.2% (40/769) of the women. Overall, 11 of the 103 GBS carriers 
(11%, 95% confidence interval 5% to 19%) were detected by the Group В Strep Test 
(Quidel); when restricted to heavily colonized carriers only (10/40), the sensitivity of the 
test was 25% (95% confidence interval 12% to 42%). 
The swabs of 10 known GBS carriers showed identical results in the Group В 
Strep Test when tested immediately and after having been frozen. No loss of antigen-
expressivity was found. 
Table 2 shows the results of the in vitro comparison of 4 rapid group В 
streptococcal antigen tests. With a bacterial concentration of 10s CFU/ml, each test scored 
negatively for all 29 strains. With a concentration of 107 CFU/ml both latex agglutination 
tests were negative for all 29 strains. The Group В Strep Test (Quidel) was positive for 7 
strains (4 slightly positive and 3 positive). The results of the ICON Strep В (Hybritech) 
were: 20 positive (5 slightly positive, 14 positive and 1 clearly positive). The concentra­
tion of 107 CFU/ml seems to be distinctive: the enzyme immunoassay tests are more 
sensitive than the latex agglutination tests and the ICON Strep В is more sensitive than 
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Table 2. In vitro results of 4 rapid antigen tests for 29 GBS strains in 3 bacterial 
concentrations. 
Test Latex agglutination tests Enzyme immunoassay tests 
Wellcome Diagnostics bioMérieux Quidel Hybritech 
CFU/ml 106 10'* 10» 106 10'* 10" 10' 10'* 10e IO6 10'* 10" 
+ + + 14 23 23 1 26 
+ + 5 4 3 3 14 3 
+ 1 4 1 5 
Total + 20 27 7 27 20 29 
29 29 9 29 29 2 29 22 2 29 9 0 
+ + + , + + , + , and - denote a clearly positive, a positive, a slightly positive, and a negative result 
respectively (degree of color reaction). 
* In a concentration of 10' CFU/ml the enzyme immunoassay tests are more sensitive than the latex 
agglutination tests and the Hybritech test is more sensitive than the Quidel test (McNemar test, ρ < 0.05). 
the Group В Strep Test (McNemar test, ρ < 0.05). When testing with a concentration of 
108 CFU/ml the ICON Strep В resulted in most positive results (29 strains), followed by 
the Group В Strep Test (27 strains), Slidex méningite Strepto В (27 strains) and Well-
cogen Strep В (20 strains) respectively. 
Discussion 
A program of disease prevention requires reliable identification of persons at risk 
and availability of effective preventive treatment. Effective therapy for prevention of early 
onset neonatal GBS sepsis is available, but identification of parturients at risk to transmit 
the disease still poses a problem. Risk factors such as low birthweight, preterm labor, 
prolonged rupture of membranes, intrapartum fever, prolonged labor and others should be 
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recognized [2, IS], while intrapartum screening for GBS carriership would be ideal. 
Screening is generally defined as the presumptive identification of a disease or 
defect by the use of an examination or test procedure that can be applied rapidly, easily, 
and relatively inexpensively. The GBS antigen kits can be performed within 10 minutes 
and are easy to use, although it is questionable whether this counts for a busy clinician at 
nightly hours as well as for a trained laboratory technician. The costs are relative, 
depending on the prevalence of GBS, management protocols and prevention of morbidity 
in a specific clinical setting. 
A test searching for a serious process in which non-treatment would have greater 
consequences than treatment would need to be quite sensitive, to avoid that patients are 
placed at risk because of non-treatment. We found a disappointing overall sensitivity of 
11% (25% for heavy colonization) using the Group В Strep Test (Quidel) compared with 
a selective GBS culture. The built-in positive control gives such a distinct degree of 
colour reaction that it is only equalled by the samples of very heavily colonized 
parturients. 
We found quite a discrepancy between the performance of the Quidel test for 
heavy vaginal colonization compared to the in vitro results. Most probably the lower in 
vivo sensitivity is the result of interference factors that exist for vaginal swabs: 
contamination with blood, mucus, and amniotic fluid. These factors are likely to 
negatively influence the antigen-expressivity of a vaginal GBS population, compared to a 
more standardized population growing under optimal conditions in Todd-Hewitt broth. 
Moreover, it is known that rupture of the membranes in the in vivo situation may cause a 
'washout' effect, reducing the bacterial concentration [16]. Information from the literature 
on the discrepancy between rapid GBS antigen testing in vivo and in vitro is scant. A few 
authors reported results that seem to support our findings [17,18]. 
Sensitivities of rapid GBS antigen tests reported in the literature show a wide 
variation (table 3) [8,17-29,31-34]. The highest overall sensitivities are found after a 
preincubation step, thereby limiting the rapid character of the test [33,34]. It should be 
noted that some of the studies mentioned used non-selective blood agar rather than 
selective medium to culture GBS. It is therefore possible that the actual prevalence of 
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Table 3. Performance specifications from published evaluations of rapid GBS 
antigen tests. 
Method Reference Trademark No of No culture Sens * Spec % Remark 
women pos (h с )t 








































































































* Sensitivity, t heavy colonization, X specificity 
A preincubation in enrichment broth for 5-7 hours, В preincubation for 60 minutes, С preincubation for 8-12 hours, D study popu­
lation moderate/ heavy colonization 
8977 1585 26% 100% A 
1062 105 15% (29%) 99% 
250 6 33% 95% 
464 52 40% (67%) 99% 
431 19 58% 93% 
344 37 62% (95%) 99% 
200 22 14% (50%) 93% 
434 64 19% (63%) 99% 
314 92 30% (76%) 93% 
4251 225 20% (57%) 99% 
4251 233 24% (62%) 99% 
500 25 88% 99% В 
1100 197 92% 98% С 
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colonization is higher, making the true sensitivities of the rapid tests even lower. 
Furthermore, the prevalence of GBS carriership among parturients will turn out to be 
higher when more sites (cervix, rectum) are cultured. 
Some authors take the view that identification of heavily colonized parturients 
rather than all colonized parturients may be adequate while others point to the experience 
that, though heavy colonization definitely is a high risk factor, 20-50% of colonized 
women will be missed and even scant maternal colonization can result in transmission of 
GBS to the neonate [15,19,22,35,36]. 
Although our in vitro comparison of rapid GBS antigen tests shows that the 
enzyme immunoassay tests are more sensitive than the latex agglutination tests, we 
conclude that the sensitivity in vivo still is too low to recommend the use of rapid antigen 
tests for general screening. The search for a more sensitive test or method should 
continue. 
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Abstract 
Group В streptococcus (GBS, Streptococcus agalactiae) ¡s an important cause of 
neonatal sepsis. Prevention is possible by intrapartum screening for maternal GBS 
carriership and antimicrobial treatment of colonized women with risk factors during labor. 
Conflicting results of diagnostic performance are reported both for the newly developed 
rapid GBS antigen tests and the Gram stain. 
The possible value of the Gram stain in GBS screening was investigated 
prospectively in 1020 women. Intrapartum Gram stains of the cervix from these women 
and of the introïtus from 510 of them were compared with cultures of cervix, introïtus 
and апогее tu m in a semiquantitative way. 
The sensitivity of the cervical and introitai Gram stain was 25% and 31%, 
respectively, the specificity 99% and 98%, respectively. Higher sensitivities (52% and 
44%, respectively) were found in heavily colonized parturients. No significant influence 
of rupture of the membranes was detected. There was a poor correlation between the 
number of gram-positive cocci in the Gram stain and the growth density. 
We do not recommend the routine use of the Gram stain for intrapartum GBS 
detection because of both the limited sensitivity and positive predictive value. 
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Introduction 
Early onset group В streptococcal (GBS) infections are an important cause of 
morbidity and mortality in neonates [1,2]. Important perinatal risk factors are: heavy 
maternal GBS colonization, preterm delivery and related low birth weight, preterm 
rupture of membranes, prolonged rupture of membranes ( > 12-24 h before delivery), 
intrapartum fever, maternal GBS urinary infection, and low levels of maternal serum anti-
GBS antibodies [1-5]. 
The maternal GBS carrier state plays a crucial role in detecting deliveries at risk 
for GBS related disease. As antepartum cultures are of limited value because carriership 
may be intermittent or temporary rather than permanent [6], intrapartum cultures in 
selective broth are the 'gold standard' [1,2]. However, the results are not available until 
12 to 48 hours later, which is often too late for decision making. Therefore, rapid GBS 
screening tests have been developed, including latex agglutination and enzyme 
immunoassay tests, which are based on direct identification of the group-specific 
polysaccharide antigen of GBS [7-26]. These tests may be rapid and specific, but low 
sensitivity and relative high costs are major disadvantages. In contrast, the Gram stain is 
rapid, simple, inexpensive and readily available and could be used as a screening tool, 
provided that sensitivity and specificity are acceptable. 
Literature is not unequivocal whether the Gram stain still merits a place in 
intrapartum maternal GBS screening [16,25,27-31]. We investigated the value of the 
Gram stain of specimens from different anatomical sites of the maternal genital tract for 
GBS detection in a prospective study, with special attention to risk factors for GBS 
disease. 
Subjects and methods 
Study population 
The trial, which was part of another study, was conducted from February 1, 1991 
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until December 1, 1992 in the two hospitals with obstetric service in our city. Exclusion 
criteria were: known GBS carriership, use of antibiotics during the 4 weeks before 
admission, planned caesarean section, antepartum fetal death, suspected congenital 
abnormalities, and immature labor. Gestational age, time of sampling, rupture of 
membranes, and delivery were recorded. The protocol was approved by both institutional 
ethical committees and written informed consent was obtained from all parturients 
enrolled in the trial. 
Collection of specimens 
Four cotton tipped standard swabs were taken in a fixed rank order from 1020 
women. First an anorectal culture swab was taken, after which a second culture swab was 
used to sample the posterior half of the introïtus. Using a sterile speculum, a third and 
fourth swab were rotated 360° in the cervical os to obtain specimens for preparing a 
Gram stain and for culturing, respectively. After 510 parturients were enrolled, a (second 
in rank order) extra swab was introduced to sample the introïtus for preparing another 
Gram stain. 
Swabs for preparing a Gram stain were kept in sterile tubes after sampling. 
Culture swabs, already moistened with Todd-Hewitt broth (Oxoid, Basingstoke, England) 
before sampling, were put in 5 ml Todd-Hewitt broth immediately in order to provide a 
favorable medium. All swabs were stored at 4°C to prevent bacterial overgrowth and 
processed within 24 hours in the same laboratory. 
Laboratory methods 
• Gram stain 
Gram stains were performed and the results recorded by one technician before 
culture results were available. The result was reported as positive if gram-positive cocci 
were identified in clumps, pairs, chains, or individually. In order to get a semiquantitative 
assessment, the average number of gram-positive cocci per field (lOOOx; at least 10-15 
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nonadjacent fields) was recorded. 
• Culture methods 
The culture swabs were streaked on 5 % defibrinated sheep blood agar and put into 
a selective enrichment broth (Todd-Hewitt broth, Oxoid CM 189, Basingstoke, England) 
with nalidixic acid (0.0013%) and gentamicin (0.0008%) for aerobic bacteria including 
GBS. Swabs were also cultured for anaerobic bacteria, lactobacilli and yeasts on Casman 
agar with 10 units/ml bacitracin and 5% defibrinated rabbit blood (anaerobically, 48 h at 
36°C) and Sabouraud agar (72 h at 30CC), respectively. Plates for GBS were incubated at 
36°C for 48 h, the enrichment broth was subcultured after overnight incubation at 36"C 
onto blood agar and incubated at 36°C for another 24 h. Cultures were judged 
representative when they reflected normal flora including gram-positive rods representing 
lactobacilli. Growth of GBS was judged 0-4, corresponding with only growth after 
enrichment (0), or with growth density in the streak areas, which means: 1 light, 2 
intermediate, 3 and 4 heavy colonization. GBS were identified by colony morphology, a 
positive CAMP-reaction, absence of a zone of inhibition around a bacitracin disc (0.04 
units) on Casman blood agar (18-24 h at 36°C), and a positive latex agglutination for 
group В (Streptex; Wellcome Diagnostics, Dartford, England). 
Statistical methods 
The diagnostic performance of the cervical and introitai Gram stain was analyzed 
with calculation of the sensitivity, specificity, positive predictive value, and negative 
predictive value. The degree of correlation between cervical Gram stain and culture was 
assessed using the Spearman correlation-coefficient. 
Results 
A total of 981 women were évaluable, from 475 of them both a cervical and an 
introitai Gram stain were obtained. The median interval between sampling and parturition 
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GBS growth density 
was 3.5 hours. Overall, GBS colonization was established by culture in 190 (19.4%) 
women, 108 (11.0%) being heavily colonized. Anorectal, introitai, and cervical 
colonization was found in 169 (17.2%), 139 (14.2%), and 112 (11.4%), respectively, and 
heavy colonization in 82 (8.4%), 53 (5.4%), and 33 (3.4%), respectively. 
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The cervical Gram stain detected 28 (25%) of 112 cervical carriers (figure la) and 
was false positive in 7 women. The introitai Gram stain detected 17 (31%) of the 55 
introitai carriers (figure lb; the Gram stain of the cervix of these women was positive in 
8 (15%) of the 52 cervical carriers) and was false positive in 7 women. As can be seen in 
the figure, higher growth densities correspond with better screening results. 
Sensitivity, specificity, positive and negative predictive values of the cervical and 
introitai Gram stain are given in table 1. The specificity of the Gram stain was quite 
good. However, the overall sensitivity was only 25.0% for the cervix and 30.9% for the 
introïtus. Higher sensitivities were found for both sites in heavily colonized women. 
The amniotic membranes were ruptured before sampling in 72.0% of the 
parturients. The diagnostic performance of the cervical and introitai Gram stain was not 
affected by rupture of the membranes (table 1). 
Table 1. Diagnostic performance of Gram stain compared to selective culture for 



















































* Heavy colonization: growth density 3 or 4 on blood agar, t Rupture of membranes (limited to cases in 
which moment is known with certainty). 
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The correlation between the quantitation of gram-positive cocci in the cervical 
Gram stain and the growth density was poor, as is reflected by a Spearman correlation-
coefficient of 0.44 (table 2). 
Table 2. Correlation between cervical Gram stain organism quantitation (lOOOx; 
average number of gram-positive cocci of at least 10-15 nonadjacent fields) 
and selective culture GBS growth density.* 
Selective culture GBS growth density 


























































* Spearman correlation-coefficient 0.44. 
Discussion 
The quick and accurate intrapartum detection of GBS carriers is the Achilles' heel 
of current preventive strategies with antibiotics, treating colonized parturients in case risk 
factors are present. Rapid GBS antigen tests, using samples of the vaginal introïtus in 769 
women comparable to the population in the present study, yielded an overall sensitivity of 
11% and of 25% in heavily colonized women only [26]. Considering this poor sensitivity, 
réévaluation of the Gram stain seems justified. 
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Beforehand, the diagnostic performance of the Gram stain can not be expected to 
be very high, because the level of detection is > 10M05 bacteria/ml sample fluid 
compared to à i o 2 bacteria/ml sample fluid for a culture in selective broth, the 'gold 
standard.' We found sensitivities of 25% and 31% for the Gram stain of the cervix and 
introïtus, respectively. Specificities were 99 and 98% respectively, remarkably higher 
than in studies reported thus far. Although these values do not differ significantly, the 
introïtus seems to be the most suitable site for genital sampling because the introitai 
colonization rate was higher than the cervical colonization rate. Moreover, in another 
study, we found the GBS vertical transmission rate to be highest in women with introitai 
colonization (in press). In addition, introitai sampling is less inconvenient for women. 
Holls et al. advocated the use of the cervical Gram stain as an appropriate test to 
assist in evaluation of GBS colonization in an at-risk population and reported a sensitivity 
and specificity of 93 and 69%, respectively [27]. Feld and Harrigan, using a vaginal 
Gram stain in a selected high risk population, found a sensitivity of 100% and a 
specificity of 66,7%, as compared to vaginal culture results [28]. The study of Sandy et 
al. however, does not support the idea that the cervicovaginal Gram stain could be a 
useful screening tool, because the sensitivity and specificity was 38 and 61%, 
respectively, in a preterm population presenting with preterm rupture of membranes or 
preterm labor [29]. In 1990, Carey et al. concluded from their results that most gram-
positive cocci seen in the Gram stain are probably anaerobes or micrococci and that the 
vaginal Gram stain at delivery is neither sensitive (34%) nor specific (72%) enough to be 
valuable as a tool in the diagnosis of maternal GBS carriage [30]. In a comparative study 
with an enzyme-linked immunosorbent assay, Towers et al. reported a sensitivity of 45% 
and a specificity of 63% for the cervicovaginal Gram stain in a high risk population [16]. 
In 1993, Hagay et al. made an identical comparison and found a sensitivity of 20% and a 
specificity of 89% for the endocervical Gram stain, and therefore do not recommend it as 
a screening test [25]. 
Some of the differences in the sensitivity and specificity of the Gram stain reported 
in the literature may be explained by the level of contamination with gram-positive 
vaginal flora. Cervical specimens could well be less contaminated than introitai 
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specimens, the rectum serving as a GBS reservoir. 
Heavy genital GBS colonization involves a higher rate of vertical transmission and 
is a well known risk factor for early onset neonatal sepsis. Towers et al., studying 20 
GBS carriers, found that the sensitivity of the Gram stain did not change as the colony 
count increased, in contrast to the increased sensitivity of a rapid enzyme-linked 
immunosorbent assay test [16]. Our results in 112 cervical and 55 introitai carriers, 
however, indicate that the sensitivity of the Gram stain is also increased in heavily 
colonized women. These data are supported by those of the The Vaginal Infections and 
Prematurity Study Group', reported by Carey et al., who found a sensitivity of 40% for 
heavy colonization and an overall sensitivity of 28% [30]. 
For future studies, Holls et al. suggested that it would be instructive to compare 
the Gram stain organism quantitation with the culture-demonstrated level of colonization.27 
Making this comparison, we found a poor correlation (table 2). Carey et al. found no 
correlation between the number of gram-positive cocci or even their presence and the 
isolation of GBS in laboring women, but a strong correlation with the isolation of 
Gardnerella vaginalis and the impression of bacterial vaginosis [30]. 
Prematurity is another major risk factor for early onset neonatal sepsis. Gestational 
age is not expected to influence the diagnostic performance of the Gram stain. Carey et 
al. found an association between the isolation of GBS and gram-positive cocci on the 
Gram stain in patients with preterm labor, but the correlation was not great enough to be 
of clinical value [30]. 
Rupture of the amniotic membranes may cause a 'wash out' effect, reducing the 
genital bacterial colonization [32]. The duration of this effect is unknown. In studying the 
influence of the membrane status on the performance of the Gram stain, we could not 
detect significant differences before and after rupture. Carey et al. did find an association 
between the presence of gram-positive cocci and the isolation of GBS in the presence of 
ruptured membranes, but the predictive value was again too small to be of clinical value 
[30]. 
We conclude that, although the diagnostic performance of the Gram stain seems 
comparable to that of present rapid GBS antigen tests for intrapartum GBS detection both 
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in sensitivity and specificity, routine use can not be recommended because of limited 
sensitivity and positive predictive value. 
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Chapter 6 
Abstract 
The in vitro susceptibilities of important perinatal pathogens to Chlorhexidine, 
hexetidine, and bacitracin were determined. 
Chlorhexidine was the most active agent in vitro against Chlamydia trachomatis, 
Ureaplasma urealyticum. Mycoplasma hominis. Streptococcus agalactiae, Escherichia 
coli, and Listeria monocytogenes. Hexetidine was not active against C. trachomatis and E. 
coli and bacitracin was only active against the gram-positive bacteria but less so than the 
other agents. 
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Introduction 
Perinatal infections continue to pose a major problem in obstetrics and pediatric 
medicine and it would be desirable to have a safe and efficacious antimicrobial agent that 
could be applied to the vaginal mucosa intrapartum to prevent microbial contamination of 
the newborn during birth. We studied the in vitro activities of three potentially useful 
agents Chlorhexidine [1,2], hexetidine [3] and bacitracin against representive strains of the 
important causes of perinatal infections. Although bacitracin is only active against gram-
positive bacteria, it might prove useful against Streptococcus agalactiae which remains 
the leading cause of life-threatening perinatal infections in the developed world. 
Materials and methods 
Microorganisms 
The organisms tested included 5 genital isolates of Chlamydia trachomatis and type 
E strain BOUR С trachomatis ATCC VR348B, 4 clinical isolates of Ureaplasma 
urealyticum, U. urealyticum ATCC 27618 and U. ureatyticum ATCC 27813, 4 clinical 
isolates oí Mycoplasma hominis, M. hominis ATCC 14027 and M. hominis ATCC 23114, 
50 clinical isolates of Streptococcus agalactiae, S. agalactiae ATCC 13813 and 5. 
agalactiae NTCC 8181, 50 clinical isolates of Escherichia coli and E. coli ATCC 25922 
and 10 clinical isolates oí Listeria monocytogenes. Staphylococcus aureus ATCC 29213 
was used as a control. 
Antimicrobial agents 
Chlorhexidine digluconate was obtained as a 20% w/v solution (Centrafarm, Etten-
Leur, The Netherlands) and was diluted to 2 g/L in 50% glycerol. Hexetidine was 
obtained both as pure substance (Parke-Davis, Orléans, France), and as a solution of 1 
g/L in water with 52 g/L alcohol for oral disinfection (Warner-Lambert, Amsterdam, The 
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Netherlands). Pure hexetidine was diluted with 1 % w/v Tween 80 in distilled water and 
used to test the susceptibilities of S. agalactiae, E. coli, L. monocytogenes and S. aureus, 
while the disinfecting solution was used to test C. trachomatis, U. urealyticum and M. 
hominis because solvents used for solubilization of the pure substance are toxic to cultures 
of these organisms. Bacitracin was obtained as a dry powder of 65,000 IU/g 
(Apothekernes Laboratorium AS, Oslo, Norway). Solutions of bacitracin and further 
dilutions of the other drugs were made in phosphate buffered saline, pH 7.2. Each agent 
was diluted two-fold to provide concentrations of 0.25 to 1,024 mg/L of Chlorhexidine, 4 
to 256 mg/L of hexetidine and 1 to 8,192 mg/L of bacitracin. 
Susceptibility testing 
McCoy cells (Flow Laboratories, Costa Mesa, CA, USA) cultured in flat bottom 
tubes were inoculated with С trachomatis essentially as described by Heessen & 
Muytjens [4]. Growth medium for the cells consisted of Eagle's MEM with HEPES 20 
mM, 10% inactivated fetal bovine serum, 50 mg/L gentamicin and 100 mg/L 
vancomycin. Growth medium for C. trachomatis consisted of Eagle's MEM with HEPES 
20 mM, 3% inactivated fetal bovine serum, 6 g/L glucose, 50 mg/L gentamicin, 100 
mg/L vancomycin, 2.5 mg/L fungizone and 1 mg/L cycloheximide. After inoculation, the 
cultures were centrifuged for 60 min at 3,000 rpm and incubated for 72 h at 37°C. After 
incubation, cultures were homogenized and frozen at -70°C or fixed with methanol and 
stained with monoclonal antibodies labelled with fluorescein isothiocyanate (De Beer 
Medicals B.V., Hilvarenbeek, The Netherlands). Inclusion bodies of C. trachomatis were 
detected by fluorescence microscopy. A suspension of 20,000 inclusion forming units/mL 
was mixed with 1 mL of each dilution of each drug and left for 30 min. The suspension 
was then diluted 100-fold in chlamydia growth medium and 1 mL was inoculated onto 
each of four cultures. Inclusions were detected after 72 h as stated above. The MIC was 
defined as the lowest concentration of each drug to completely inhibit the formation of 
inclusions in all four cultures. 
M. hominis was grown in 65.5 mL PPLO broth (Difco 0554, Detroit, USA) 
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supplemented with 10 mL fresh yeast extract, 10 mL fresh horse serum, 10 mL 10% w/v 
L-arginine hydrochloride, 2.5 mL 2% w/v thallium acetate and containing 0.002% w/v 
phenol red and 1,000 IU/mL penicillin with a final pH of 7.0. U. urealyticum was 
cultured in 90 mL 3% w/v Trypticase soy broth (Oxoid CM 129, Basingstoke, UK) 
supplemented with 3.6 mL fresh yeast extract, 24 mL inactivated horse serum, 3 mL 
40% w/v urea and containing 0.002% w/v phenol red, 40 mg/L cefuroxime and 4 mg/L 
fungizone with a final pH of 6.0. A suspension of 20,000 color changing units/mL was 
mixed with 1 mL of each dilution of each drug, incubated for 30 min and diluted 100-fold 
in broth medium. One millilitre was then pipetted into four culture tubes which were 
incubated for 72 h at 37°C. Growth was detected by a color change (pH shift) and the 
MIC was the lowest concentration of each drug to inhibit growth in all four tubes. 
Viable counts were determined for each untreated control to confirm the initial 
inoculum. 
S. agalactiae, E. coli, L. monocytogenes and 5. aureus were grown on blood agar 
overnight at 37°C. Doubling dilutions of the three drugs were prepared in Iso-sensitest 
broth (Oxoid CM 473, Basingstoke, UK) and mixed with an equal volume (100 ^L) 
containing IO4 CFU of each bacterial strain in the wells of microtitration plates [5]. The 
MIC was the lowest concentration of each drug to completely inhibit growth after 
overnight incubation at 37CC. 
Results and discussion 
Ninety percent of S. agalactiae were susceptible to l mg chlorhexidine/L or less 
(Table 1), 90% of all E. coli and L. monocytogenes were susceptible to 2 mg/L. MICs 
for С trachomatis, U. urealyticum and M. hominis ranged from 16-512 mg/L, with C. 
trachomatis being the most susceptible. Hexetidine inhibited S. agalactiae and L. 
monocytogenes at concentrations of 8 mg/L or less, U. urealyticum and M. hominis were 
inhibited by 64-128 mg/L and E. coli and C. trachomatis were resistant to the highest 
concentrations used. Bacitracin inhibited S. agalactiae at concentrations of 128 mg/L or 
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Chlorhexidine, hexetidine and bacitracin have been used in obstetrics and 
gynecology for several purposes and are potentially suitable agents for vaginal disinfection 
because they are not absorbed to any large extent [2]. However, bacitracin has little to 
offer as the drug exhibits a narrow spectrum, was only moderately active against S. 
agalactiae and some strains were resistant as has been shown previously [6]. Our data 
suggest that S. agalactiae and L. monocytogenes would be sufficiently susceptible to 
hexetidine in vitro for the local concentrations achieved by applying 0.1% solution to 
provide effective vaginal antisepsis as has been shown preoperatively [7] and with 
suppositories containing the agent [3]. Hexetidine has also been shown to reduce the 
vaginal micoflora, especially S. agalactiae, without affecting the lactobacilli that may play 
a protective role in maintaining the vaginal ecology 13]. However, hexetidine seems 
unsuitable for perinatal antisepsis as it offers no activity against E. coli which is a 
significant neonatal pathogen nor did it exhibit activity against С trachomatis at any of 
the concentrations tested. 
Furr & Taylor-Robinson reported an inhibitory effect of 1 % Chlorhexidine cream 
on M. hominis [1] and vaginal application of the disinfectant during labor has been 
proposed for preventing early onset neonatal infections by S. agalactiae due to vertical 
transmission [8,9]. We found that more than 90% of all S. agalactiae and E. coli were 
inhibited by 0.5-1 mg/L and 2 mg/L Chlorhexidine respectively whereas С trachomatis 
were inhibited by 16-64 mg/L which is in agreement with Christensen et al. [10] and 
Nisbet et al. [11]. Chlorhexidine therefore appears to be the best choice for vaginal 
antisepsis. Assuming that the surface area of the normal vagina during labor to be of the 
order of 250 cm2, and that a volumetric MIC of 512 mg/L is equivalent to a surface MIC 
of 0.064 mg/cm2, a 10 mL solution of 1 % Chlorhexidine (e.g. Hibitane, Zeneca, The 
Netherlands) would result in local concentrations of 0.4 mg/cm2 which would exceed the 
concentrations required to inhibit all the organisms we tested by a factor of 6. A large 
clinical trial is now in progress to assess the efficacy of Chlorhexidine in preventing 
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Chapter 7 
Abstract 
The effect of vaginal disinfection with Chlorhexidine gel during labor on vertical 
transmission of group В streptococcus was studied, as a method to prevent vertical 
transmission and subsequent neonatal early onset group В streptococcal disease. 
A total of 1020 parturients were randomized to one of three groups as soon as 
labor started. In all parturients, anus, introïtus, and cervix were cultured 
semiquantitatively. Two groups were treated double-blindly with 10 ml of either a 0.3% 
Chlorhexidine gel or a placebo gel, applicateti around the portio and into the fornices. A 
second application was given after 10 hours if labor still continued. The third group 
received no treatment. Ear, pharynx, and umbilicus of all newborns were also cultured 
semiquantitatively. 
981 women were évaluable. The overall incidence of group В streptococcal 
carriership was 19.4%. Vertical transmission was 52.4% in the Chlorhexidine group, 
71.4% in the placebo group and 66.7% in the control group (p=0.069). When testing the 
transmission rates for the Chlorhexidine versus the combined placebo plus control group 
(69.3%), the difference was 16.9% (p=0.026). 
Vaginal disinfection with a Chlorhexidine gel during labor modestly reduces group 
В streptococcal vertical transmission. Because the method is cheap, simple and safe, it 
should be considered for routine use. Our results indicate that it may reduce the incidence 
of early onset group В streptococcal sepsis by 2-32%. 
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Introduction 
Group В beta-hemolytic streptococcus (GBS, Streptococcus agalactiae) is the 
leading cause of neonatal sepsis with eventual meningitis and accounts for 10 to 25% of 
postpartum maternal bacteremia [1,2]. Invasive neonatal GBS infections present 
themselves either as 'early' (usually within 24 hours) or 'late onset' (7 days-3 months) 
disease. Early onset infections make up two thirds of cases and are usually acquired by 
vertical transmission from the mother's genital tract [1,2]. Asymptomatic maternal genital 
GBS colonization may be intermittent or temporary rather than permanent and occurs in 4 
to 40% (usually about 20%) of pregnant women, depending on the population studied and 
culture technique used [1-3]. The rectum serves as a reservoir for colonization of the 
vagina, and genital tract isolation rates are reported highest from the lower vagina 
(introïtus) and lowest from the cervix [1,2]. In infants born of GBS carriers vertical 
transmission ranges from 40 to 70%, the higher percentage being associated with a high 
genital inoculum. Despite high prevalence rates for vertical transmission, the incidence of 
early onset GBS infection is only 1-10/1000 live births. Albeit a small group, prevention 
is important because of the high mortality rate: 50 to 70% in older studies, and 13 to 
37% more recently [1,2]. Furthermore, about half of the infants surviving GBS meningitis 
are left with permanent neurologic sequelae. 
There is no consensus on the best approach to prevent early onset GBS infection 
[4]. It is important to recognize perinatal risk factors, including low birthweight, preterm 
delivery, prolonged rupture of membranes, intrapartum fever, and heavy maternal GBS 
colonization [1,2,5]. Infants of mothers with low levels of serogroup-specific antibodies 
against GBS are at risk [1]. A program of active immunization aimed at pregnant women 
or, alternatively, all women in the childbearing years, would probably be most efficacious 
in controlling perinatal GBS disease. However, an effective vaccine is not yet available 
[6]. Antibiotic treatment during pregnancy is not adequate [7], neither can single-dose 
penicillin prophylaxis in infants be recommended [8]. Intrapartum prevention with 
antibiotic therapy (ampicillin, penicillin G) has been shown to reduce GBS vertical 
transmission [9-16]. Vaginal Chlorhexidine disinfection during labor has been proposed as 
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a simple, cheap, and safe [17] alternative without risk for development of bacterial 
resistance and only a very low risk for allergic complications [18-20]. It can be used not 
only in delivery wards, but also in home deliveries and in the developing world. 
Chlorhexidine might reduce the transmission of other potential pathogens as well. 
Moreover, as compared to antibiotic therapy, Chlorhexidine disinfection would obviate the 
necessity of selection. The omission of rapid GBS antigen tests would be advantageous, as 
they lack sufficient sensitivity so far [21]. 
In 1992, Chlorhexidine disinfection during labor was reported to reduce excess 
neonatal morbidity associated with GBS [22]. However, the effect on vertical transmission 
was not investigated. Stimulated by the promising results of a small clinical pilot study 
[20], we investigated the effect of vaginal Chlorhexidine gel disinfection on vertical 
transmission of GBS in a randomized trial. 
Subjects and methods 
Subjects and design 
The trial was conducted from February 1991 through November 1992 in the two 
hospitals with obstetric service in the city of Nijmegen, The Netherlands. Eligible 
pregnant women received written information on the trial during pregnancy, or at 
admission to the delivery ward. Exclusion criteria were: known GBS carriership (allowing 
responsible obstetricians to take different preventive measures), use of antibiotics during 
the 4 weeks before admission, planned caesarean section, antepartum fetal death, 
suspected congenital abnormalities, and immature labor. The protocol was approved by 
both institutional ethical committees and written informed consent was obtained from all 
parturients enrolled in the trial. 
The goal of the trial was to study the effect of Chlorhexidine disinfection on the 
rate of GBS transmission to the neonate. Secondary goals were to study the vertical 
transmission rates of Escherichia coli, Staphylococcus aureus, and Candida albicans, and 
to establish neonatal and maternal morbidity. 
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Two groups were treated in a double-blind manner with either a Chlorhexidine or a 
placebo gel. To detect any possible effect of treatment with placebo gel, a third group 
received no treatment at all. A pre-study calculation of the required sample size was 
performed, assuming the prevalence of GBS among parturients to be 20%. With the 
probability of making a type I (a) and type II (ß) error set at 0.05 and 0.20 respectively, 
and considering that a reduction in assumed normal GBS transmission rate of 50% to 
25% or less would be of clinical importance, we estimated that data from about 340 
deliveries per group would be required for the study. A total of 1020 participating women 
were randomly assigned to one of three groups according to a predefined block 
(10:10:10) allocation scheme on the moment labor had clearly started. 
Intervention 
As in our pilot study, we used a viscous gel to apply the Chlorhexidine because it 
adheres well to the mucosa and is a good lubricant [20]. The active gel consisted of 
Chlorhexidine digluconate (3.0 g), hydroxypropylmethylcellulose 4000 centiPoise (20.0 g), 
100 ml glycerol, natrium hydroxide to obtain a pH of 7.0, and water to a volume of 1000 
ml. After mixing, the viscous aqueous solution was transferred into glass bottles and 
sterilized (20 min at 120°C). This product was transferred into disposable sterile syringes 
and stored at 4°C. The placebo gel had the same composition except for the Chlorhexidine 
digluconate and was handled identically. There were no visual differences between the 
syringes containing the different gels. 
For the duration of the trial all antiseptic solutions and lubricants for obstetric use 
were abandoned from the wards and instead sterilized placebo gel was available in 100 ml 
glass bottles being perishable after 24 hours when opened. When a woman was in active 
labor, the attending obstetrician applied 10 ml gel (brought at room temperature) from the 
syringe attached to a 14 cm plastic catheter around the portio and into the fornices. This 
procedure was repeated after 10 hours in case delivery had not yet occurred. For this 




All parturients were cultured before the application of any gel. Cotton tipped 
wooden swabs were used, moistened with Todd-Hewitt broth, with addition of 8% 
lecithin and 3% Tween 80 to inactivate any Chlorhexidine remnants absorbed in the swab 
[23]. First an anorectal swab was taken, after which a second swab was used to sample 
the posterior half of the introïtus. Using a sterile speculum, a third swab was rotated 360° 
in the cervical os to obtain a cervical specimen. Ear, pharynx, and umbilicus of all 
neonates were cultured directly after birth. 
All swabs were stored at 4°C and inoculated within 24 hours in the same 
bacteriological laboratory. The following media were used to plate the swabs 
semiquantitatively: 5% defibrinated sheep blood agar (48 h at 36°C), Casman agar with 
10 units/ml bacitracin and 5% defibrinated rabbit blood (anaerobically, 48 h at 36°C), 
and Sabouraud agar (72 h at 30°C). Sabouraud agar and Casman agar were used to detect 
yeasts and Haemophilus influenzae respectively, the latter also being recognized as an 
important cause of neonatal infections [24]. After plating, the swabs were put in a 
selective enrichment broth consisting of Todd-Hewitt broth with ^ g nalidixic acid per 
ml and 8μg gentamicin per ml. After overnight incubation at 36°C the swabs were plated 
on blood agar and incubated at 36°C for another 24 hours. The growth density of 
microorganisms (1, 2, 3, or 4), expressed as growth in the corresponding streak area, on 
the directly plated agar plates was determined. Growth density 0 was scored if GBS were 
only isolated from the enrichment broth (or if only 1-2 colonies of other species were 
grown on blood agar). The identification of GBS was confirmed by a positive CAMP-
reaction, absence of a zone of inhibition around a bacitracin disc (0.04 units) on Casman 
blood agar (18-24 h at 36°C), and a group В latex agglutination test (Streptex, Wellcome 
Diagnostics). 
Standard forms were used to record the data of mother and child. Prenatal data 
included information on age, ethnic origin, obstetric history, assessment of gestational 
age, use of drugs, alcohol, and nicotine, any loss of blood, tocolysis, anemia, and 
diabetes mellitus or gestational diabetes. 
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In addition to the usual parameters of labor and delivery, data also included time 
of rupture of membranes, admission to the delivery ward and application(s) of gel. 
Moreover, the following data were recorded: cervical dilatation at the moment of 
application of gel, number of vaginal examinations, use of internal monitoring, fetal blood 
sampling, and infection parameters. Initial infant data were collected and whether the 
infant received intensive, special or regular care. 
Women and infants were followed up during their hospital stay with special 
attention to infectious problems, results of additional cultures, and antibiotic therapy. 
Neonatal septicemia, meningitis and pneumonia were diagnosed in case of positive culture 
of blood, cerebrospinal fluid or tracheal aspirate, respectively. 'Probable infection' was 
based on clinical suspicion with negative cultures. Follow up was continued until 3 
months and all women and their family doctors received a questionnaire for this purpose. 
In case of twins, data on the first-born were processed only. Any spontaneously reported 
complaints were recorded. 
Statistics 
The Kruskal-Wallis test, Fisher's exact test, logistic regression analysis, and 
repeated measurement analysis of categorical data [25] were used for statistical analyses. 
Results 
Of the 1020 participating women, 522 were enrolled in one hospital and 498 in the 
other. Thirty-nine were not évaluable because cultures were incomplete or lost, or 
delivery took place before any gel could have been applicated. Of the 981 analyzed 
mother-infant pairs 327 were assigned to the Chlorhexidine group, 328 to the placebo 
group, and 326 to the control group. In total, 19 (1.9%) twin pregnancies and 41 (4.2%) 
premature deliveries were enrolled. Table 1 summarizes a number of characteristics of the 
3 groups; no significant differences were found. Overall, GBS carriership was established 
in 190 (19,4%) of 981 women, 108 (56.8%) of the carriers being heavily colonized 
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Table 1. Characteristics of enrolled parturients by group assignment. 
Characteristic* 
Age (years), mean (SD) 
Pregnancy, median (range) 
Parity, median (range) 
Gestational age (days) 
mean (SD) 
P5;P95 
Ethnic origin (% non-Caucasian) 




Number of GBS carriers (%) 










3.4/ 5.8/ 4.9 












6.4/ 6.7/ 5.2 
















* No significant differences between the three groups; means and medians tested with the Kruskal-Wallis 
test; percentages tested with two tailed Fisher's exact test; growth densities tested for each culture site. 
t heavy colonization. 
(growth density 3 or 4). Anorectal, introitai, and cervical colonization was found in 169 
(88.9%), 139 (73.2%), and 112 (58.9%) of carriers respectively, the differences being 
statistically significant (p<0.001 [25]). Genitals plus anorectum were colonized in 
67.9%, only the genitals in 11.1% and just the anorectum in 21.1 % of the carriers. 
Pregnancy characteristics of intrapartum GBS carriers were compared to that of 
non-carriers (table 2). No differences in obstetric histories were found, nor in the use of 
tocolytic therapy during pregnancy or in gestational age at delivery. More insulin 
dependent diabetes mellitus was found in the GBS carrier group (two tailed Fisher's exact 
test, ρ=0.05), while non-carriers suffered from anemia more often (two tailed Fisher's 
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Table 2. Pregnancy characteristics by intrapartum GBS carrier state. 
Characteristic 
Obstetric history 
г 1 immature/premature deliv­
ery (%) 
2: 1 intra-uterine death (%) 
г 1 perinatal mortality (%) 






















Prolonged (>24h) rupture of 13.2 
membranes (%) 
Insulin dependent diabetes mellitus (%) 2.1 
Gestational diabetes (%; diet and/or 4.7 
insulin) 
Vaginal bleeding after 20 gestational 2.6 
weeks (%) 











Use of alcohol (%) 
nicotin (%) 
drugs (%) 
Use of corticosteroids (%) 































Time 1st gel — birth (nun), median (P5, P95) 
> 30 mm (%) 
Time ROMt - birth (h). median (P5, P95) 
2nd Stage of labor (min), median (P5, P95) 
ROMt before 1st gel application (%) 
Maternal temperature г 38°C {%) 
Maternal leukocytosis > 16x10»/! (%) 
Foul smelling amniotic fluid (%) 
Fetal tachycardia > 160 beats/mm (%) 
No of vaginal examinations, mean (SD) 
Internal monitoring (%) 
Fetal blood sampling (%) 
Fetal distress (%) 
Instrumental delivery (%) 
258 (42. 844) 
98 4 
7 2 ( 0 9 .30 1) 











207 (32, 830) 
95 7 
7 2 (0 3. 35 6) 


























Sex (% male) 
Birth weight (g), mean (SD) 
5 Minute Apgar score, mean (SD) 
pH of umbilical artery, mean (SD) 
Pediatric involvement (%) 






9 6 (0 9) 







9 4 ( 1 0 ) 







9 4 (0 9) 





* No significant differences between the three groups, except for the % of neonates admitted to the (special) neonatal care umt 
(p=0 012), means and medians tested with the Kmskal-Wallis test, percentages tested with two tailed Fisher's exact test f Rupture of 
membranes 
110 
Intrapartum vaginal Chlorhexidine disinfection 
exact test, p=0.04). 
Group assignment of GBS carriers did not significantly influence the clinical 
characteristics of deliveries and infants at birth (table 3). In 98.4% of the Chlorhexidine 
group assigned GBS carriers the gel was applicated more than 30 minutes before birth. A 
second gel application was given in 5.8% of the total Chlorhexidine group and 4.9% of 
the placebo group. Gel was administered after the membranes had ruptured in 70.0% of 
GBS carriers. The median interval between admission and the first application of gel was 
3.5 hours for both gel-treated groups. The median cervical dilatation at the first 
application of gel was 4 cm. No significant differences in infection parameters were 
detected between the three groups of GBS colonized parturients. Group assignment had no 
influence on the condition of infants born of GBS carriers, although significant more 
infants from both the Chlorhexidine and control group were admitted to the special care 
unit, as compared to the neonates from the placebo group (two tailed Fisher's exact test, 
p=0.012). 
The vertical transmission rate of S. agalactiae was lower in the Chlorhexidine 
group, but the difference did not reach significance (two tailed Fisher's exact test, 
p=0.069; table 4). When testing the transmission rate for the Chlorhexidine group 
(52.4%) versus that for the combined placebo plus control group (69.3%), the difference 
of 16.9% (95% confidence interval (CI) 2.2-31.6%) was significant (two tailed Fisher's 
exact test, p=0.026; one tailed Fisher's exact test, p=0.017). These transmission rates 
resulted in 10.1%, 15.2%, and 11.7% neonatal GBS colonization in the Chlorhexidine, 
placebo, and control group respectively. Logistic regression analysis for the maternal 
carriers, with correction for the treatment group (no interactions), reveals the introïtus as 
the colonization site yielding the highest GBS vertical transmission rate (odds ratio 10.2; 
95% CI 4.3-24.5). 
No significant differences in transmission rates of E. coli, S. aureus, and C. 
albicans were found between the three groups (two tailed Fisher's exact test; table 4). 
Overall, transmission rates of microorganisms declined in the following order: S. 
agalactiae (63.5%), S. aureus (53.9%), E. coli (35.6%), and С albicans (32.7%). The 
degree of neonatal colonization with the various microorganisms, reflected by the 
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Table 4. Vertical transmission rates of frequent perinatal pathogens and 
corresponding semiquantitative sumscore of growth densities for infants by 
group assignment. 
Pathogen 















































































* Percentages tested with two tailed Fisher's exact test; medians tested with the Kruskal-Wallis test, t Cases 
with positive neonatal culture(s) while negative maternal culture(s) for concerning pathogen are excluded. 
t Total score (growth density + 1) of ear, pharynx, and umbilicus (range 0-15). 
sumscore of the growth densities for all three culture-sites, did not differ significantly 
among the three groups (Kruskal-Wallis test; table 4). Haemophilus species (not 
associated with morbidity) were cultured from two women in the Chlorhexidine group: H. 
influenzae type В only from one cervix and Haemophilus parainfluenzae from the introïtus 
of both women. Only the ear of one symptom-free neonate, born of a non-colonized 
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woman from the control group, was colonized with H. influenzae (non type B). Microbial 
growth, which can be considered as a quality control of sample and culture techniques, 
was present in 95.1% of all maternal cultures (n=2943), and in 90.5% of neonatal 
cultures from the placebo plus control groups (n=1962). 
Follow-up data until three months postpartum were obtained from all 981 mother-
infant pairs. No significant differences between the three groups of GBS colonized 
mothers were detected, regarding the incidence of temperature > 38CC, endometritis, 
wound infection (following perineal rupture, episiotomy, or caesarean section), antibiotic 
therapy, and various other infectious complications. Neither was this the case between the 
control groups of GBS carriers and non-carriers (n=269). No cases of endometritis or 
wound infection were registered among GBS carriers. Among the non-carriers (n=791), 4 
suffered from endometritis and 2 from infected wounds, caused by other pathogens than 
GBS. 
There was no mortality among the infants born of GBS carriers. One male infant 
(3635 g at 295 gestational days), born of a heavily colonized GBS carrier from the 
Chlorhexidine group, suffered from early onset GBS sepsis and was discharged after 
successful treatment with ampicillin and gentamicin. The membranes had ruptured 3 
hours before the application of gel and some signs of infection were present during labor. 
Another boy, whose mother was heavily colonized with E. coli but not with GBS, and 
treated with placebo gel, suffered from pneumonia (E. coli and S. aureus) and was also 
successfully treated with ampicillin and gentamicin without further sequelae. 
Two children born of non-carriers died: a small-for-gestational-age term boy at 
age 3 months from cot death and a girl within the first week due to transposition of the 
great vessels. 
There were no significant differences regarding the incidence of 'probable 
infection', antibiotic therapy, and duration of hospital stay for various neonatal reasons, 
between the three groups of infants born of GBS carriers. The same was true for the 
infants born of mothers from the control groups of carriers and non-carriers. 




Colonization rates for the anorectum, introïtus, and cervix support the concept that 
the lower gastrointestinal tract is the principal reservoir for GBS. The introïtus seems the 
most suitable site for screening, in view of the high GBS vertical transmission rate and 
relatively high GBS isolation rate at this location. 
Maternal diabetes was identified as a risk factor for GBS colonization, as earlier 
reported by Baker [26]. 
In contrast to our pilot study [20], a modest reduction in vertical transmission rate 
of S. agalactiae by Chlorhexidine gel was found in the present, first randomized, study. 
In the non-randomized pilot study however, the vagina was cleaned with saline before the 
application of the 0.3% Chlorhexidine gel and only cervix and anus of parturients were 
cultured. Moreover, 0.01% benzalkoniumchloride was added to the gel as a preservative, 
any extra disinfecting effect, although unlikely in view of the high Chlorhexidine 
concentration, not being excluded. 
In 1992 the Swedish Chlorhexidine Study Group concluded that intravaginal 
Chlorhexidine flushing during labor reduced morbidity among full-term newborn infants 
compared to placebo treatment with saline [22]. Parturients were cultured from the 
posterior fornix for GBS only. The infants were not cultured to assess the vertical 
transmission rate of GBS. The excess morbidity among the infants born of GBS carriers 
was only statistically significant, when respiratory disorder and (probable) infection were 
taken together, while infection alone did not reach significance. Culture-proven 
septicemia/meningitis occurred in one infant of both groups of GBS carriers. Parturients 
delivering prematurely were not included, nor was a second control group receiving no 
treatment at all to assess the impact of flushing the vagina with saline. 
It is known that Chlorhexidine kills 99% of vaginal bacteria within 5 minutes [18]. 
In 98.4% of parturients Chlorhexidine gel was applicated more than 30 minutes before 
birth, while the median interval was 4.3 hours. Although no experimental data for 
Chlorhexidine are available yet, the use of a gel as a vehiculum may have advantages over 
an aqueous solution, such as a longer duration of action, as is the case for povidone-
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iodine gel [27]. Activity of Chlorhexidine is reduced in the presence of serum, blood, pus 
and other organic matter [17]. This problem will be overcome by using a sufficiently high 
concentration [18]. The Chlorhexidine concentration used in our study was 600 times or 
more the minimal bactericidal concentration for GBS [28] and at least as high as in other 
clinical studies [19,20,22]. 
Preferably, Chlorhexidine is applicated before rupture of the membranes, as the 
risk for ascending colonization and infection of the genital tract increases substantially 
after membrane rupture. The prevalence of positive genital cultures for GBS is 
significantly lower immediately after rupture of the membranes [29]. This may be due to 
a "wash out" effect and/or inherent bacteriostatic properties of amniotic fluid [30]. The 
duration of this effect is not known. Reduction of vaginal pathogens by Chlorhexidine and 
thereupon amniorrhexis would seem most beneficial. In the present study, in only 30% of 
GBS carriers the Chlorhexidine gel was given before the membranes ruptured. In these 
cases transmission occurred in 44%, being 56% when gel was applicated after the 
membranes ruptured. For the placebo group these percentages were 77% and 69% 
respectively. 
The effect of Chlorhexidine might be increased by earlier application, preferably 
before membrane rupture, and possibly by increasing the concentration and/or quantity. 
Randomizing patients during pregnancy instead of during labor could probably have 
gained time in this trial. Earlier application in routine use is possible because there is no 
need for the time-consuming process of enrolling, randomizing and culturing of a trial. 
We conclude that vaginal disinfection with 0.3% Chlorhexidine gel during labor 
modestly reduces vertical transmission of GBS. This raises the question of whether this 
reduction is of sufficient clinical importance to implement Chlorhexidine disinfection in 
clinical practice. We theorize that the qualitative and quantitative reduction in vertical 
transmission in the Netherlands (195,000 deliveries/year) may subsequently lead to a 
reduction by 4 to 62 cases of an estimated annual 195 cases of early onset GBS sepsis. 
The costs of implementation can roughly be calculated analogous to the costs of a 
comparable product as catheter lubricant. This is manufactured at an industrial scale and 
purchased at prices of about Dfl. 2.50 per ready to use unit. The price of such products is 
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mainly dependent on the costs of manufacturing and the applicator tip, whereas the 
ingredients contribute less than 5% to the final costs. The use of 250,000 packages/year 
would cost Dfl. 0.63 million. The financial benefit would result from fewer admissions to 
neonatal intensive care units (average Dfl. 30,000/neonate) and less handicapped children 
(up to Dfl. 2 million/lifetime). Assuming that early onset GBS sepsis will leave 1 out of 8 
neonates severely handicapped, the total benefit would range between Dfl. 1.12-17.36 
million/year. Because the method is cost-effective and simple and safe as well, it should 
be considered for routine use, not as a panacea but as a contribution to the prevention of 
GBS infections in newborns. 
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Historically considered as a cause of bovine mastitis, group В streptococcus in the 
second half of the twentieth century became one of the leading causes of life-threatening 
neonatal infections in the western world [1]. Although decreased in the past decades, the 
mortality rate of early onset GBS infections still is 13-37% at present. We found a 
mortality rate of 23 % among 78 neonates with early onset GBS invasive disease between 
1985 and 1993. A substantial number of surviving infants is left with sequelae, especially 
following GBS meningitis. 
Strategies to prevent this burden are mainly an obstetrical responsibility. Although 
effective prevention through intrapartum antibiotic treatment of parturients has been 
documented [2], no consensus exists on how and when women receiving this regimen 
should be selected. In view of the risk of bacterial resistance, adverse reactions, and the 
considerable costs of large-scale antibiotic treatment there is a need to target this strategy 
on deliveries at high risk for GBS disease. There may be a role for vaginal disinfection 
with Chlorhexidine during labor as a basic preventive strategy without the necessity of 
screening and selection. In the future, active immunization of women may prove to be a 
promising strategy, although its efficacy will be limited due to non-responders and 
incomplete protection of preterm neonates [3]. 
Risk factors associated with early onset infection 
Knowledge of risk factors seems crucial in preventing early onset GBS infections. 
Major risk factors are preterm delivery, preterm rupture of membranes, prelabor rupture 
of membranes, and intrapartum signs of infection. In addition to these easily recognizable 
risk factors information on other major risk factors is less readily available. These include 
heavy genital GBS colonization and low levels of serotype-specific antibody to the GBS 
capsular polysaccharide in maternal serum. GBS urinary infection is considered to be a 
likely indicator of heavy genital colonization. Minor risk factors include multiple births, 
congenital anomalies, prolonged labor, assisted delivery, age less than 20 years, and, 
perhaps, black race and diabetes mellitus. Women with a previous child that suffered 
invasive GBS disease require special attention. 
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It is important to be on the alert for major risk factors as they greatly increase the 
risk for early onset infection. However, absence of risk factors does not exclude serious 
infections. In almost 20% of the 78 studied cases with early onset disease we established 
none of the easily recognizable risk factors. 
Screening 
GBS colonization is a prerequisite for early onset GBS disease and heavy 
colonization increases the risk. Therefore, screening pregnant women for GBS carriership 
enables prophylactic regimens to be targeted on deliveries at risk. The 'gold standard' is a 
culture in selective broth. Non-selective media greatly diminish the detection of GBS. 
The lower vagina (introïtus) seems to be the most suitable site for sampling with 
optional addition of an anorectal sample. Isolation rates are highest from the anorectum, 
the lower gastrointestinal tract probably being the principal GBS reservoir, but genital 
colonization is associated with a higher frequency of transmission than anorectal 
colonization. In the genital tract, introitai colonization rates are higher than cervical 
colonization rates. Moreover, we found the GBS vertical transmission rate to be highest 
in women with introitai colonization. In addition, introitai sampling is less inconvenient 
for women. 
Antenatal cultures have a predictive value for colonization at delivery that varies 
inversely with the interval to delivery. Therefore, screening is best performed during 
labor but the time needed to obtain the result limits the use of cultures. Rapid GBS 
screening tests have been developed to overcome this limitation. However, currently 
available rapid tests do not seem to have brought the solution. 
Among the really rapid tests (result within 1-2 hours) are latex agglutination and 
enzyme immunoassay tests, based on the demonstration of the group-specific 
polysaccharide antigen of GBS. An in vitro comparison of two commercially available 
latex agglutination tests (Wellcogen Strep B, Wellcome Diagnostics; Slidex méningite 
Strepto B, bioMérieux) and two enzyme immunoassay tests (Group В Strep Test, Quidel; 
ICON Strep B, Hybritech) showed the latter tests to be more sensitive. An in vivo 
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evaluation of the sensitivity of one of these enzyme immunoassay tests (Group В Strep 
Test, Quidel) in lower vaginal samples of 769 parturients demonstrated an overall 
sensitivity of 11% and a sensitivity for heavy colonization of 25%. Considering this poor 
sensitivity, the Gram stain was re-evaluated as a GBS screening test because it is rapid, 
simple, inexpensive and readily available. We found an overall sensitivity of 31% for the 
Gram stain of the introïtus. Because of the limited sensitivity of all current rapid 
screening tests we conclude that routine use can not be recommended. 
As a rapid and sufficiently sensitive screening test is yet lacking, a selective 
culture, although depending on local laboratory facilities, seems to be most informative in 
clinical practice. Instead of screening all parturients and starting antibiotic prophylaxis in 
GBS carriers with a risk factor, limitation of screening to women with a risk factor can 
be an alternative strategy. A sample for a selective culture could be taken as soon as a 
risk factor arises. In cases of threatening preterm labor and preterm rupture of 
membranes the result will often be available in time to start antibiotic prophylaxis. This 
will also be true in cases of prelabor rupture of membranes, especially when the situation 
is managed conservatively. If the result for women in active labor is not yet available, the 
choice whether or not to start antibiotic prophylaxis may depend on local factors including 
the incidence of early onset infections in the population concerned. 
Modifications in culture technique may yield results more quickly and could prove 
to be a fruitful area for future research, parallel to the search for a more sensitive rapid 
antigen test. A non-perishable selective broth inoculated and incubated at 37°C on the 
delivery ward and yielding results within 4-6 hours might be an attainable goal. 
Modifications of starch serum broth media for detecting pigment production by GBS have 
been developed in the 1970s [4-6], receiving little attention in the last decade as they 
seemed overshadowed by the newer rapid antigen tests. Pigment production by GBS, 
which is orange in color and has characteristics of a caretenoid, was already noted by 
Lancefield in 1934 [7]. It is only seen under anaerobic conditions and is both highly 
specific and sensitive for ß hemolytic strains of GBS, while non-hemolytic strains do not 
produce pigment [8,9]. Historically, the search for modifications in culture technique to 
accelerate the detection of hemolytic streptococci, was already reported by Rivett et al. in 
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1933 [10]: 'If we wished to know as quickly as possible whether a particular case was 
infected by hemolytic streptococci the swab was incubated in a tube of nutrient broth, to 
which a drop or two of sterile blood had been added, and the fluid kept in constant 
motion by means of Ridley hydro-dynamic mixing machine. After incubation for five or 
six hours, the presence of hemolytic streptococci was revealed by commencing hemolysis 
of the blood-corpuscles and the finding of many streptococci in a film of the broth.' 
Vaginal Chlorhexidine disinfection during labor 
Although it can not be expected to have any influence on established infection in 
utero, vaginal Chlorhexidine disinfection during labor seemed an attractive alternative to 
antibiotic prophylaxis as a method to prevent vertical transmission and subsequent 
neonatal early onset group В streptococcal disease. It is simple and cheap, has no risk for 
development of bacterial resistance and only a very low risk for allergic reactions and 
would obviate the necessity of selection. A non-randomized clinical pilot study of 
Chlorhexidine disinfection in our hospital was very promising [11]. Other potentially 
useful agents against perinatal pathogens could be hexetidine and bacitracin. Our in vitro 
studies showed Chlorhexidine to be the most active agent. The Swedish Chlorhexidine 
Study Group reported that intravaginal Chlorhexidine flushing during labor reduced 
morbidity among full-term neonates compared to placebo treatment with saline [12]. This 
thesis presents the first randomized trial of the effect of Chlorhexidine on vertical 
transmission. Chlorhexidine disinfection modestly reduced vertical transmission by 16.9% 
(95% confidence interval 2.2-31.6%) compared to the combined placebo plus control 
group. Although the effect might be increased by earlier application, higher 
concentrations or larger quantities, it does not seem to offer a full alternative to antibiotic 
prophylaxis. However, because it is simple, safe and cost-effective, routine use in all 
deliveries irrespective of the location should be considered, as a contribution to the 
prevention of GBS infections. 
125 
Chapter 8 
Management in general practice 
It should be stressed that no consensus exists on the best approach to prevent early 
Table 1. A practical proposal to prevent neonatal early onset GBS infections. 
In general: 
* knowledge of and alertness for major risk factors is crucial: preterm delivery, 
preterm rupture of membranes, prelabor rupture of membranes, intrapartum signs 
of infection, heavy genital GBS colonization, GBS urinary infection, low levels of 
serotype-specific antibody to the GBS capsular polysaccharide in maternal serum 
* if a risk factor arises: selective culture of introïtus (rapid GBS antigen tests and 
Gram stain are not recommended) 
* only GBS carriers with a risk factor: antibiotic prophylaxis 
* clinical chorioamnionitis: broad spectrum antibiotics intravenously without delay 
and irrespective of GBS colonization 
Pregnancy: whether maternal GBS colonization is associated with preterm rupture of 
membranes and/or preterm delivery is controversial and was not studied in this thesis; 
although not well-established, the following is proposed: 
* GBS bacteriuria: antibiotic treatment orally 
* previous prematurely born child with invasive GBS disease: (monthly) culture of 
introïtus starting in midtrimester and antibiotics orally if culture positive 
Labor and delivery: 
* consider vaginal Chlorhexidine disinfection as a basic strategy in all parturients 
* antibiotics intravenously only in GBS colonized parturients with a risk factor (2 g 
amoxycillin/ampicillin followed by 1-2 g every 4-6 h until delivery) 
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onset GBS infections. Any preventive strategy will be depending on a number of local 
factors, including the background GBS carriage rate, the proportion of patients with 
perinatal risk factors, and availability of screening methods. There seems to be fairly high 
agreement that antibiotic prophylaxis needs to be focused only on GBS colonized 
parturients with recognizable risk factors. Any selective strategy, however, will miss 
some cases of neonatal infections. No single strategy, including any future vaccination 
program, can be expected to solve the issue completely. Therefore, the optimal strategy 
can not be formulated. 
A 'rule of thumb', meeting the requirements of a rational and cost-effective policy 
based on present knowledge and possibilities could, however, facilitate management in 
clinical practice. To conclude the thesis, a practical proposal to prevent early onset GBS 
infections in our country is presented (table 1). 
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The first chapter places perinatal infections due to species of the genus 
Streptococcus in a historical perspective. Some clinical differences and parallels between 
infectious diseases caused by group В streptococcus (Streptococcus agalactiae, GBS) and 
group A streptococcus (Streptococcus pyogenes) are stressed. The main objective of the 
thesis is described: the prevention of neonatal GBS disease from an obstetric point of 
view. 
Being the leading cause of neonatal septicemia in developed countries, GBS causes 
a considerable psychosocial and economic burden. In the second chapter the literature on 
the prevention of neonatal septicemia due to GBS is reviewed. Clinical manifestations, 
epidemiologic data on GBS disease, and risk factors associated with early onset GBS 
infection are described. As screening for maternal GBS colonization is part of most 
preventive strategies, different rapid screening tests are reviewed and compared to the 
'gold standard', a culture in a selective broth. The optimal timing (during labor) and site 
(vaginal introïtus) for screening are discussed. Preventive strategies can be divided in 
chemoprophylaxis and immunoprophylaxis. The latter may prove to be a promising future 
strategy. To date, intrapartum antibiotic treatment of colonized parturients with a risk 
factor is the most rewarding approach. Vaginal disinfection with Chlorhexidine during 
labor may offer a contribution to prevention in addition. 
The third chapter reports on a retrospective study of neonatal early onset GBS 
infection in a tertiary care hospital over a nine-year period. Morbidity, mortality, as well 
as risk factors and prognostic factors were established. The overall mortality rate among 
78 patients with early onset GBS disease was 23%. Almost 30% of survivors with known 
outcome had long-term sequelae. Nine of these 14 patients were severely brain damaged. 
In 82% of all cases at least one of the investigated risk factors was present. Low birth 
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weight was not an independent risk factor, but reflected gestational age. There were no 
sequelae among patients with symptoms of GBS disease occurring after 6 hours. 
Mortality and adverse outcome rate were higher in infants with low gestational age or low 
5 minute Apgar scores. Early treatment resulted in less mortality, but did not reduce 
sequelae. Alertness to GBS infection, even in the absence of risk factors, remains crucial 
for early treatment and good outcome. 
In the fourth chapter a prospective study is presented which evaluates the 
sensitivity of an enzyme immunoassay test (Group В Strep Test, Quidel) for GBS 
screening in 769 parturients. The overall sensitivity was 11% and sensitivity for heavy 
colonization was 25%. The Group В Strep Test was also compared in vitro with another 
enzyme immunoassay test (ICON Strep B, Hybritech) and two latex agglutination tests 
(Wellcogen Strep B, Wellcome Diagnostics; Slidex méningite Strepto B, bioMérieux). In 
vitro, the enzyme immunoassay tests were more sensitive than the latex agglutination 
tests. However, sensitivity in vivo is too low to recommend the use of rapid antigen tests 
for general screening. 
The fifth chapter describes a study establishing the diagnostic performance of the 
Gram stain for rapid intrapartum GBS screening in 1020 women. The sensitivities of the 
Gram stain of the cervix and introïtus were 25% and 31%, respectively. Specificities 
were 99% and 98%, respectively. Higher sensitivities were found in heavily colonized 
women. The diagnostic performance was not significantly affected by rupture of the 
membranes. A poor correlation between the number of gram-positive cocci in the Gram 
stain and the selective culture GBS growth density was found. Routine use of the Gram 
stain for intrapartum GBS detection is not recommended because of both limited 
sensitivity and positive predictive value. 
In the sixth chapter, a study of the in vitro activity of Chlorhexidine and two other 
potentially useful antimicrobial agents, hexetidine and bacitracin, against important 
perinatal pathogens is presented. Chlorhexidine was the most active agent in vitro against 
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Chlamydia trachomatis, Ureaplasma urealyticum. Mycoplasma hominis. Streptococcus 
agalactiae, Escherichia coli, and Listeria monocytogenes. Hexetidine was not active 
against C.trachomatis and E. coli. Bacitracin was only active against the gram-positive 
bacteria but less so than the other agents. 
The main study of this thesis is described in the seventh chapter. It studies the 
effect of vaginal disinfection with a 0.3% Chlorhexidine gel during labor on vertical 
transmission of GBS, as a method to prevent vertical transmission and subsequent 
neonatal early onset GBS disease. A total of 1020 parturients were randomized to one of 
three groups as soon as labor started. Two groups were treated double-blindly with either 
Chlorhexidine or placebo gel, the third group receiving no treatment. The overall 
incidence of GBS carriership was 19.4%. Vertical transmission was 52.4% in the 
Chlorhexidine group, 71.4% in the placebo group and 66.7% in the control group 
(p=0.069). A significant difference of 16.9% (p=0.026) was found when testing the 
transmission rates for the Chlorhexidine group versus the combined placebo plus control 
group. Vaginal disinfection with a Chlorhexidine gel during labor modestly reduces GBS 
vertical transmission. Because the method is simple, safe and cost-effective it should be 
considered as a basic preventive strategy in all deliveries. 
Finally, the eighth chapter integrates the studies presented in this thesis and some 
areas for future research are suggested. Although the optimal strategy to prevent neonatal 
early onset GBS disease can not be formulated with current knowledge , a 'rule of thumb' 
meeting the requirements of a rational and cost-effective policy could facilitate 





Hoofdstuk één plaatst perinatale infecties ten gevolge van species van het genus 
Streptococcus in historisch perspectief. Enkele klinische verschillen en parallellen tussen 
infectieuze ziekten veroorzaakt door de groep В streptococ (Streptococcus agalactiae, 
GBS) en de groep A streptococ (Streptococcus pyogenes) worden belicht. De belangrijkste 
doelstelling van het proefschrift wordt omschreven: de preventie van neonatale GBS-
infecties vanuit obstetrisch gezichtspunt. 
De GBS is de voornaamste oorzaak van neonatale sepsis in ontwikkelde landen en 
brengt aanzienlijke psychosociale en economische schade met zich mee. In hoofdstuk 
twee wordt een overzicht gegeven van de literatuur over de preventie van neonatale GBS-
sepsis. Klinische uitingsvormen, epidemiologische gegevens over GBS-infecties en risico­
factoren die in verband worden gebracht met de vroege vorm ('early onset') van GBS-
sepsis worden beschreven. Aangezien screening op maternale kolonisatie met GBS 
onderdeel is van de meeste preventieve strategieën, worden verschillende snelle 
screeningstests besproken en vergeleken met de vloeibare selectieve kweek als 'gouden 
standaard'. Het optimale tijdstip (tijdens de bevalling) en de beste locatie (introïtus 
vaginae) voor screening worden besproken. Preventieve strategieën kunnen worden 
verdeeld in chemoprofylaxe en immunoprofylaxe. De laatstgenoemde strategie lijkt 
veelbelovend. Tot op heden is antibiotische behandeling van gekoloniseerde barenden met 
een risicofactor de succesvolste benadering. Aanvullend lijkt vaginale desinfectie met 
chloorhexidine tijdens de baring te kunnen bijdragen aan preventie. 
In hoofdstuk drie wordt verslag gedaan van een retrospectieve studie naar 'early 
onset' GBS-infecties in een derdelijns ziekenhuis gedurende een periode van negen jaar. 
Morbiditeit, mortaliteit alsmede risicofactoren en prognostische factoren werden vastge-
steld. De totale mortaliteit onder 78 patientjes met 'early onset' GBS-sepsis bedroeg 23%. 
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Van de overlevenden waarvan de afloop bekend is, had bijna 30% restverschijnselen op 
lange termijn. Negen van deze 14 patientjes leden aan ernstige hersenbeschadiging. In 
82% van alle gevallen was tenminste één van de onderzochte risicofactoren aanwezig. 
Laag geboortegewicht was geen onafhankelijke risicofactor maar weerspiegelde de zwan-
gerschapsduur. Patientjes bij wie de symptomen van GBS-infectie na 6 uur optraden, 
vertoonden geen restverschijnselen. De mortaliteit en het percentage restverschijnselen 
waren hoger bij kinderen van korte zwangerschapsduur of lage Apgar score na 5 minuten. 
Vroege behandeling resulteerde in minder mortaliteit, maar niet in minder restverschijnse-
len. Alertheid op GBS-infectie, zelfs bij afwezigheid van risicofactoren, blijft cruciaal 
voor een vroege behandeling en een goede afloop. 
In hoofdstuk vier wordt een prospectieve studie gepresenteerd, die de sensitiviteit 
van een enzymimmuno-assay test (Group В Strep Test, Quidel) ter opsporing van de GBS 
evalueert bij 769 barenden. De totale sensitiviteit was 11 % en de sensitiviteit voor zware 
kolonisatie was 25%. De Group В Strep Test werd in vitro ook vergeleken met een 
andere enzymimmuno-assay test (ICON Strep В, Hybritech) en twee latex-agglutinatie 
tests (Wellcogen Strep В, Wellcome Diagnostics; Slidex méningite Strepto В, 
bioMérieux). In vitro waren de enzymimmuno-assay tests gevoeliger dan de latex-
agglutinatie tests. In vivo is de sensitiviteit echter te laag om het gebruik van snelle 
antigeen tests aan te bevelen voor algehele screening. 
Hoofdstuk vyf beschrijft een studie naar de diagnostische waarde van het Gram 
preparaat voor snelle screening op de GBS tijdens de baring bij 1020 vrouwen. De 
sensitiviteit van het Gram preparaat van de cervix en introïtus bedroeg respectievelijk 
25% en 31%. De specificiteit was respectievelijk 99% en 98%. Een hogere sensitiviteit 
werd gevonden bij zwaar gekoloniseerde vrouwen. De diagnostische waarde werd niet 
significant beïnvloed door het breken van de vliezen. Er werd een zwakke correlatie 
gevonden tussen het aantal gram-positieve coceen in het Gram preparaat en de GBS-
groeidichtheid in de selectieve kweek. Routinematig gebruik van het Gram preparaat voor 
opsporing van de GBS tijdens de baring wordt niet aangeraden, zowel vanwege de 
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beperkte sensitiviteit als de beperkte positief voorspellende waarde. 
In hoofdstuk zes wordt een studie beschreven naar de in vitro activiteit van 
chloorhexidine en twee andere mogelijk bruikbare antimicrobiële middelen, hexetidine en 
bacitracine, tegen belangrijke perinatale pathogenen. Chloorhexidine was in vitro het 
meest werkzame middel tegen Chlamydia trachomatis, Ureaplasma ureatyticum, Myco-
plasma hominis, Streptococcus agalactiae, Escherichia coli en Listeria monocytogenes. 
Hexetidine was niet werkzaam tegen С. trachomatis en E. coli. Bacitracine was slechts 
werkzaam tegen gram-positieve bacteriën, maar minder dan de andere middelen. 
De hoofdstudie van dit proefschrift staat beschreven in hoofdstuk zeven. Hierin 
wordt het effect onderzocht van vaginale desinfectie met een 0,3% chloorhexidine-gel 
tijdens de baring op de verticale transmissie van de GBS. Dit als een methode om vertica-
le transmissie en de hieruit volgende neonatale 'early onset' GBS-sepsis te voorkomen. In 
totaal werden 1020 barenden gerandomiseerd in drie groepen zodra zij in partu raakten. 
Twee groepen werden dubbelblind behandeld met chloorhexidine- dan wel placebo-gel, 
terwijl de derde groep niet werd behandeld. De totale incidentie van GBS-dragerschap 
was 19,4%. Verticale transmissie vond plaats bij 52,4% van de chloorhexidinegroep, 
71,4% van de placebogroep en 66,7% van de controlegroep (p=0,069). Er werd een 
significant verschil van 16,9% (p=0,026) gevonden indien de mate van transmissie in de 
chloorhexidinegroep werd vergeleken met die in de gecombineerde placebo- plus 
controlegroep. Vaginale desinfectie met een chloorhexidine-gel tijdens de baring geeft een 
bescheiden reductie in verticale transmissie van de GBS. Omdat de methode simpel, veilig 
en kosten-effectief is, zou zij overwogen moeten worden als basale preventieve strategie 
bij alle bevallingen. 
In hoofdstuk acht tenslotte worden de in dit proefschrift beschreven studies 
geïntegreerd en worden enkele suggesties gedaan voor toekomstig onderzoek. Hoewel de 
optimale strategie ter preventie van de neonatale 'early onset' GBS-sepsis met de huidige 
kennis niet kan worden geformuleerd, zou een 'vuistregel' die voldoet aan de eisen van 
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rationaliteit en kosten-effectiviteit het beleid in de klinische praktijk kunnen verge-
makkelijken. Een praktisch voorstel voor Nederland wordt gepresenteerd. 
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behorende bij het proefschrift 
Group В Streptococcus and Childbirth 
Obstetric Prevention of Neonatal Early Onset Group В Streptococcal Sepsis 
1 De letaliteit van de neonatale 'early onset' groep В Streptococcen sepsis bedraagt 
ook thans nog zo'η 23% (dit proefschrift) 
2 De introïtus vaginae is de meest geschikte plaats voor het afnemen van een kweek 
ter detectie van maternaal dragerschap van groep В Streptococcen (dit proefschrift) 
3 Routinematig gebruik van de huidige snelle screeningstests ter detectie van groep 
В Streptococcen kan niet worden aangeraden vanwege onvoldoende sensitiviteit (dit 
proefschrift) 
4 Vaginale desinfectie met chloorhexidine tijdens de baring dient bij iedere zwangere 
overwogen te worden als preventieve basismaatregel (dit proefschrift) 
5 Who would not give a trifle to prevent what he would give a thousand worlds to 
cure? (Edward Young, 1683-1765) 
6 Kennis van en alertheid op risicofactoren voor neonatale groep В Streptococcen 
sepsis zal ook bij ontbrekende kennis over maternaal dragerschap reeds bijdragen 
aan preventie 
7 Het is aannemelijk dat aanzienlijk meer kinderen gehandicapt zijn door infecties 
dan door zuurstoftekort tijdens de bevalling (G.H.A. Visser, Oratie Universiteit 
Utrecht, 1992) 
8 Niet alles wat een moeder op haar kind overdraagt is even gunstig 
9 Hoewel het fenomeen arts-onderzoeker voor sommige sceptici een contradictio in 
terminis is, betreft het eerder een bedreigde soort 
10 De Cochrane Collaboration brengt middels 'evidence-based medicine' de weten­
schappelijke waarheid onder de aandacht van medisch practici, die op hun beurt de 
kloof tussen deze kennis en de praktijk met inzicht moeten zien te overbruggen 
A.H. Adriaanse 
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